Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act :

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares of the registrant’s common stock outstanding as of ~~August 1, 2008~~February 6, 2009 was ~~29,368,498.~~28,993,962.


	Fiscal Quarter Ended						Nine Months Ended						Fiscal Quarter Ended
	June 27, 2008			June 29, 2007			June 27, 2008			June 29, 2007			January 2, 2009			December 28, 2007
Sales
Products	$	206,498		$	195,634		$	625,322		$	584,314		$	175,854		$	204,175
Services		37,951			31,461			104,723			90,649			32,382			33,256

Total sales		244,449			227,095			730,045			674,963			208,236			237,431

Cost of sales
Products		116,457			107,644			342,951			317,783			94,523			111,157
Services		21,809			17,532			60,733			50,067			18,392			18,972

Total cost of sales		138,266			125,176			403,684			367,850			112,915			130,129

Gross profit		106,183			101,919			326,361			307,113			95,321			107,302

Operating expenses
Selling, general and administrative		68,797			64,366			202,380			190,822			60,916			65,980
Research and development		18,519			16,879			53,889			48,592			14,514			17,180
Purchased in-process research and development		1,488			—			1,488			—

Total operating expenses		88,804			81,245			257,757			239,414			75,430			83,160

Operating earnings		17,379			20,674			68,604			67,699			19,891			24,142
Impairment of private company equity investment (Note 14)		—			—			(3,018	)		—
Interest income		1,200			1,622			4,888			4,259			587			1,937
Interest expense		(390	)		(454	)		(1,274	)		(1,444	)		(322	)		(449	)

Earnings before income taxes		18,189			21,842			69,200			70,514			20,156			25,630
Income tax expense		6,823			7,291			24,463			24,326			7,115			8,046

Net earnings	$	11,366		$	14,551		$	44,737		$	46,188		$	13,041		$	17,584

Net earnings per share:
Basic	$	0.39		$	0.48		$	1.50		$	1.52		$	0.45		$	0.58

Diluted	$	0.38		$	0.47		$	1.48		$	1.49		$	0.45		$	0.57

Shares used in per share calculation:
Basic		29,340			30,469			29,833			30,497			28,854			30,330

Diluted		29,728			30,983			30,309			31,028			28,950			30,900

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.


	June 27, 2008		September 28, 2007		January 2, 2009		October 3, 2008
ASSETS
Current assets
Cash and cash equivalents	$	128,215	$	196,396	$	116,929	$	103,895
Accounts receivable, net		189,192		187,429		169,815		199,420
Inventories		184,790		140,533		159,626		161,039
Deferred taxes		38,175		38,068		33,605		33,618
Prepaid expenses and other current assets		19,277		17,332		15,112		15,663

Total current assets		559,649		579,758		495,087		513,635
Property, plant and equipment, net		114,975		110,792		109,499		110,343
Goodwill		230,430		193,760		205,513		218,208
Intangible assets, net		42,664		31,572		31,197		36,972
Other assets		20,376		20,951		25,035		24,089

Total assets	$	968,094	$	936,833	$	866,331	$	903,247

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities
Current portion of long-term debt	$	—	$	6,250
Accounts payable		78,603		72,588	$	65,097	$	70,923
Deferred profit		10,531		13,641		11,037		10,957
Accrued liabilities		173,007		159,109		149,639		167,173

Total current liabilities		262,141		251,588		225,773		249,053
Long-term debt		18,750		18,750		18,750		18,750
Deferred taxes		7,302		4,050		3,923		4,341
Other liabilities		44,206		44,358		46,912		43,431

Total liabilities		332,399		318,746		295,358		315,575

Commitments and contingencies (Notes 5, 6, 8, 9, 10, 11, 12 and 15)
Commitments and contingencies (Notes 6, 7, 9, 10, 11, 12, 13, 15 and 19)

Stockholders’ equity
Preferred stock—par value $0.01, authorized—1,000 shares; issued—none		—		—		—		—
Common stock—par value $0.01, authorized—99,000 shares; issued and outstanding—29,350 shares at June 27, 2008 and 30,345 shares at September 28, 2007		360,067		351,330
Common stock—par value $0.01, authorized—99,000 shares; issued and outstanding—28,954 shares at January 2, 2009 and 28,917 shares at October 3, 2008						359,201		356,192
Retained earnings		182,981		199,471		198,870		186,009
Accumulated other comprehensive income		92,647		67,286		12,902		45,471

Total stockholders’ equity		635,695		618,087		570,973		587,672

Total liabilities and stockholders’ equity	$	968,094	$	936,833	$	866,331	$	903,247

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.


	Nine Months Ended						Fiscal Quarter Ended
	June 27, 2008			June 29, 2007			January 2, 2009			December 28, 2007
Cash flows from operating activities
Net earnings	$	44,737		$	46,188		$	13,041		$	17,584
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization		21,217			21,163			6,843			6,834
Gain on disposition of property, plant and equipment		(452	)		(196	)		(27	)		(222	)
Impairment of private company equity investment		3,018			—
Purchased in-process research and development		1,488			—
Share-based compensation expense		7,207			7,890			2,366			1,719
Deferred taxes		(540	)		(1,802	)		113			765
Unrealized gain on currency remeasurement								(6,686	)		(329	)
Changes in assets and liabilities, excluding effects of acquisitions:
Accounts receivable, net		10,735			2,245			24,570			13,773
Inventories		(31,046	)		(9,703	)		(7,942	)		(15,152	)
Prepaid expenses and other current assets		490			(436	)		(107	)		272
Other assets		(726	)		(212	)		(1,029	)		(24	)
Accounts payable		1,222			(6,488	)		(3,618	)		(1,372	)
Deferred profit		(3,966	)		(3,269	)		303			(2,254	)
Accrued liabilities		3,200			272			(15,619	)		(3,319	)
Other liabilities		3,041			3,613			4,723			(1,172	)

Net cash provided by operating activities		59,625			59,265			16,931			17,103

Cash flows from investing activities
Proceeds from sale of property, plant and equipment		1,265			3,193			5,166			341
Purchase of property, plant and equipment		(16,674	)		(10,879	)		(6,943	)		(3,459	)
Purchase of businesses, net of cash acquired		(52,898	)		(5,066	)		(726	)		(9,987	)
Private company equity investments		(18	)		—

Net cash used in investing activities		(68,325	)		(12,752	)		(2,503	)		(13,105	)

Cash flows from financing activities
Repayment of debt		(6,250	)		(2,500	)
Repurchase of common stock		(81,892	)		(69,582	)		(279	)		(15,102	)
Issuance of common stock		15,761			26,748			909			9,518
Excess tax benefit from share-based plans		3,151			7,070			—			2,390
Transfers to Varian Medical Systems, Inc.		(600	)		(381	)		(146	)		(212	)

Net cash used in financing activities		(69,830	)		(38,645	)
Net cash provided by (used in) financing activities								484			(3,406	)

Effects of exchange rate changes on cash and cash equivalents		10,349			9,317			(1,878	)		692

Net (decrease) increase in cash and cash equivalents		(68,181	)		17,185
Net increase in cash and cash equivalents								13,034			1,284
Cash and cash equivalents at beginning of period		196,396			154,155			103,895			196,396

Cash and cash equivalents at end of period	$	128,215		$	171,340		$	116,929		$	197,680

See accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.

These unaudited interim condensed consolidated financial statements of Varian, Inc. and its subsidiary companies (collectively, the “Company”) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The ~~September 28, 2007~~October 3, 2008 balance sheet data was derived from audited financial statements, but does not include all disclosures required in audited financial statements by U.S. GAAP. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended ~~September 28, 2007~~October 3, 2008 filed with the SEC. In the opinion of the Company’s management, the unaudited interim condensed consolidated financial statements include all normal recurring adjustments necessary to present fairly the information required to be set forth therein. The results of operations for the ~~nine months~~fiscal quarter ended ~~June 27, 2008~~January 2, 2009 are not necessarily indicative of the results to be expected for a full year or for any other periods.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

The Company designs, develops, manufactures, markets, sells and services scientific instruments (including analytical instruments, research products and related software, consumable products, accessories and services) and vacuum products (including related accessories and services). These businesses primarily serve life science, ~~industrial (which includes~~ environmental, ~~food~~energy, and ~~energy), academic~~applied research and ~~research~~other customers.

Until April 2, 1999, the business of the Company was operated as the Instruments Business of Varian Associates, Inc. (“VAI”). On that date, VAI distributed to the holders of its common stock one share of common stock of the Company and one share of common stock of Varian Semiconductor Equipment Associates, Inc. (“VSEA”), which was formerly operated as the Semiconductor Equipment business of VAI, for each share of VAI (the “Distribution”). VAI retained its Health Care Systems business and changed its name to Varian Medical Systems, Inc. (“VMS”). Transfers made to VMS under the terms of the Distribution are reflected as financing activities in the Unaudited Condensed Consolidated Statement of Cash Flows.

Fiscal Periods. The Company’s fiscal years reported are the 52- or 53-week periods ending on the Friday nearest September 30. Fiscal year ~~2008~~2009 will comprise the ~~53-week~~52-week period ending October ~~3, 2008,~~2, 2009, and fiscal year ~~2007~~2008 was comprised of the ~~52-week~~53-week period ended ~~September 28, 2007.~~October 3, 2008. The fiscal quarters ended January 2, 2009 and ~~nine months ended June 27, 2008 and June 29,~~December 28, 2007 each comprised 13 ~~weeks and 39 weeks, respectively.~~weeks.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Comprehensive Income.A summary of the components of the Company’s comprehensive income follows:


	Fiscal Quarter Ended					Nine Months Ended				Fiscal Quarter Ended
	June 27, 2008			June 29, 2007		June 27, 2008		June 29, 2007		January 2, 2009			December 28, 2007
(in thousands)
Net earnings	$	11,366		$	14,551	$	44,737	$	46,188	$	13,041		$	17,584
Other comprehensive (loss) income:
Currency translation adjustment		(3,048	)		6,673		25,359		25,440		(32,569	)		824

Total other comprehensive (loss) income		(3,048	)		6,673		25,359		25,440		(32,569	)		824

Total comprehensive income	$	8,318		$	21,224	$	70,096	$	71,628
Total comprehensive (loss) income										$	(19,528	)	$	18,408

Effective October 4, 2008 (the first day of fiscal year 2009), the Company adopted Statement of Financial Accounting Standards No. (“SFAS”) 157,Fair Value Measurements. The Company elected to delay applying SFAS 157 to certain non-recurring nonfinancial assets and nonfinancial liabilities until fiscal year 2010, as permitted by FASB Staff Position (“FSP”) 157-2,Effective Date of FASB Statement No. 157.

On the same date, the Company also adopted SFAS 159,The Fair Value Option for Financial Assets and Liabilities, which permits entities to elect, at specified election dates, to measure eligible financial instruments at fair value. The Company did not elect the fair value option under SFAS 159 for any financial assets and liabilities that were not previously measured at fair value.

Fair Value Hierarchy.SFAS 157 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are:

Level 1—Observable inputs that reflect quoted prices for identical assets or liabilities in active markets.

Level 2—Other inputs that are directly or indirectly observable in the marketplace.

Level 3—Unobservable inputs which are supported by little or no market activity.

As of January 2, 2009, the Company did not have any financial liabilities that were measured at fair value on a recurring basis. Financial assets measured at fair value on a recurring basis as of January 2, 2009 were as follow:

The fair value of the Company’s money market funds were derived from quoted market prices in active markets and accordingly were classified within Level 1 of the fair value hierarchy.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)


	June 27, 2008		September 28, 2007		January 2, 2009		October 3, 2008
(in thousands)
Inventories
Raw materials and parts	$	87,288	$	64,130	$	77,966	$	77,447
Work in process		33,153		24,842		22,815		25,091
Finished goods		64,349		51,561		58,845		58,501

Total	$	184,790	$	140,533	$	159,626	$	161,039

The Company enters into foreign exchange forward contracts to minimize the short-term impact of foreign currency fluctuations on assets and liabilities denominated in non-functional currencies. ~~These contracts are accounted for under Statement of Financial Accounting Standards No. (“SFAS”) 133,~~~~Accounting for Derivative Instruments and Hedging Activities~~. Typically, gains and losses on these contracts are substantially offset by transaction losses and gains on the underlying balances being hedged. During the fiscal quarter ~~and nine months~~ ended ~~June 27, 2008,~~January 2, 2009, net foreign currency losses relating to these arrangements were $1.1 million. During the fiscal quarter ended December 28, 2007, net foreign currency gains relating to these arrangements were $0.7 million and $1.5 million, respectively. During the fiscal quarter and nine months ended June 29, 2007, net foreign currency losses relating to these arrangements were $0.4 million and $1.2 million, respectively. These amounts were recorded in selling, general and administrative expenses.

From time to time, the Company also enters into foreign exchange forward contracts to minimize the impact of foreign currency fluctuations on forecasted transactions. These contracts are designated as cash flow hedges under SFAS 133. At June 27, 2008, there were no outstanding foreign exchange forward contracts designated as cash flow hedges of forecasted transactions. During the fiscal quarters and nine months ended June 27, 2008 and June 29, 2007, no foreign exchange gains or losses from hedge ineffectiveness were recognized.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~$0.3 million.

The Company’s foreign exchange forward contracts generally range from one to 12 months in original maturity. A summary follows of all foreign exchange forward contracts that were outstanding as of ~~June 27, 2008 follows:~~January 2, 2009:


	Notional Value Sold		Notional Value Purchased		Notional Value Sold		Notional Value Purchased
(in thousands)
Australian dollar	$	—	$	43,281	$	—	$	45,869
Euro		—		28,715		—		32,594
British pound		—		11,971		—		15,238
Swiss franc		—		4,510
Japanese yen						3,751		—
Korean won						3,079		—
Brazilian real						1,654		—
Canadian dollar		3,255		—		1,313		—
Japanese yen		3,248		—
Mexican peso						—		1,119
Swedish krona		2,337		—		1,050		—
Polish zloty		—		1,634		—		473

Total	$	8,840	$	90,111	$	10,847	$	95,293

~~Analogix Business.~~On November 11, 2007, the Company acquired certain assets and assumed certain liabilities of Analogix, Inc. (the “Analogix Business”) for approximately $11 million in cash and assumed net debt, subject to certain net asset adjustments. Under the terms of the acquisition, the Company might make additional purchase price payments of up to $4 million over a three-year period, depending on the performance of the Analogix Business and certain operational milestones. The Analogix Business designs, manufactures, markets, sells and services consumables and instrumentation for automated compound purification using flash chromatography, and became part of the Scientific Instruments segment.

~~Oxford Diffraction Ltd.~~ On April 4, 2008, the Company acquired Oxford Diffraction Ltd. (“Oxford Diffraction”) for approximately $39 million in cash and assumed net debt, subject to certain net asset adjustments. Under the terms of the acquisition, the Company might make additional purchase price payments of up to $10 million over a three-year period, depending on the future financial performance of the Oxford Diffraction business. Oxford Diffraction designs, manufactures, markets, sells and services instruments and consumables for x-ray crystallography, an analytical technique used by scientists in pharmaceutical research and other research laboratories to determine the structure of both small molecules and large molecules such as proteins. Oxford Diffraction became part of the Scientific Instruments segment.

In connection with the Oxford Diffraction acquisition, the Company has completed a preliminary valuation of identified intangible assets (including purchased in-process research and development) which was used to prepare the initial purchase price allocation for accounting purposes. This valuation is expected to be finalized in the fourth quarter of fiscal year 2008 and may result in adjustments to the final purchase price allocation.

Based on the results of the preliminary valuation, the Company recorded a one-time charge of $1.5 million during the third quarter of fiscal year 2008 to immediately expense acquired in-process research and development related to projects that were in process but incomplete at the time of the acquisition.

Contingent Consideration Arrangements. The Company is, from time to time, obligated to pay additional cash purchase price amounts in the event that certain financial or operational milestones are met by acquired

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

businesses. As of ~~June 27, 2008,~~January 2, 2009, up to a maximum of ~~$43.9~~$28.1 million could be payable through April 2011 under contingent consideration arrangements relating to acquired businesses. Amounts subject to these arrangements can be earned over the respective measurement period, depending on the performance of the acquired business relative to certain financial and/or operational targets.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The following table summarizes contingent consideration arrangements as of ~~June 27, 2008:~~January 2, 2009:

During the first quarter of fiscal year 2009, the Company paid $0.5 million in contingent consideration to the seller of the Analogix Business.

Changes in the carrying amount of goodwill for each of the Company’s reporting segments in the first ~~nine months~~quarter of fiscal year ~~2008~~2009 were as follow:

~~As required by SFAS 142,~~~~Goodwill and Other Intangible Assets~~, the Company performs an annual goodwill impairment assessment. This assessment is performed in the second quarter of each fiscal year. During the second quarter of fiscal year 2008, the Company completed its annual impairment test and determined that there was no impairment of goodwill.

The following intangible assets have been recorded and are being amortized by the Company:


	June 27, 2008							January 2, 2009
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
(in thousands)
Intangible assets
Existing technology	$	17,790	$	(9,841	)	$	7,949	$	14,907	$	(9,523	)	$	5,384
Patents and core technology		45,816		(14,117	)		31,699		36,562		(13,826	)		22,736
Trade names and trademarks		2,451		(1,884	)		567		2,382		(1,982	)		400
Customer lists		12,288		(10,399	)		1,889		12,317		(10,046	)		2,271
Other		3,144		(2,584	)		560		2,905		(2,499	)		406

Total	$	81,489	$	(38,825	)	$	42,664	$	69,073	$	(37,876	)	$	31,197


								October 3, 2008
								Gross		Accumulated Amortization			Net
(in thousands)
Intangible assets
Existing technology								$	16,503	$	(9,699	)	$	6,804
Patents and core technology									40,680		(14,253	)		26,427
Trade names and trademarks									2,425		(1,946	)		479
Customer lists									13,090		(10,278	)		2,812
Other									2,972		(2,522	)		450

Total								$	75,670	$	(38,698	)	$	36,972

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Amortization expense relating to intangible assets was ~~$2.4~~$2.1 million and ~~$6.2~~$1.9 million during the fiscal ~~quarter~~quarters ended January 2, 2009 and ~~nine months ended June 27, 2008, respectively. Amortization expense relating to intangible assets was $1.8 million and $6.1 million during the fiscal quarter and nine months ended June 29,~~December 28, 2007, respectively. At ~~June 27, 2008,~~January 2, 2009, estimated amortization expense for the remainder of fiscal year ~~2008~~2009 and for each of the five succeeding fiscal years and thereafter follows:


	Estimated Amortization Expense
(in thousands)
Fiscal quarter ending October 3, 2008	$	2,414
Fiscal year 2009		8,652
Estimated amortization expense
Nine months ending October 2, 2009			$	5,094
Fiscal year 2010		8,148		6,569
Fiscal year 2011		5,680		4,658
Fiscal year 2012		4,836		3,767
Fiscal year 2013		4,431		3,266
Fiscal year 2014				3,117
Thereafter		8,503		4,726

Total	$	42,664	$	31,197

Summary of Restructuring Plans.~~Between fiscal years 2003 and 2007, the~~The Company has committed to several restructuring plans in order to adjust its organizational structure, improve operational efficiencies and eliminate redundant or excess costs resulting from acquisitions or dispositions during those periods.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

The following table sets forth changes in the Company’s aggregate liability relating to all ongoing restructuring plans ~~(including the Fiscal Year 2007 Plan described below)~~ during the first ~~second and third quarters~~quarter of fiscal year ~~2008~~2009 as well as total restructuring expense and other related costs recorded since the inception of those plans:


	Employee- Related			Facilities- Related			Total				Employee- Related			Facilities- Related			Total
(in thousands)
Balance at September 28, 2007	$	2,222		$	707		$	2,929
Balance at October 3, 2008											$	1,840		$	982		$	2,822
Charges to expense, net		453			761			1,214				925			—			925
Cash payments		(181	)		(131	)		(312	)			(601	)		(38	)		(639	)
Foreign currency impacts and other adjustments		24			(24	)		—				47			(56	)		(9	)

Balance at December 28, 2007		2,518			1,313			3,831
Charges to expense, net		51			—			51
Cash payments		(1,020	)		(65	)		(1,085	)
Foreign currency impacts and other adjustments		36			138			174

Balance at March 28, 2008		1,585			1,386			2,971
Charges to expense, net		294			—			294
Cash payments		(107	)		(88	)		(195	)
Foreign currency impacts and other adjustments		(4	)		(21	)		(25	)

Balance at June 27, 2008	$	1,768		$	1,277		$	3,045
Balance at January 2, 2009											$	2,211		$	888		$	3,099


Total expense since inception of plans
(in millions)
Restructuring expense							$	19.2		Restructuring expense							$	7.1

Other restructuring-related costs⁽¹⁾							$	8.1		Other restructuring-related costs⁽¹⁾							$	6.9

Fiscal Year 2009 First Quarter Plan. During the first quarter of fiscal year 2009, the Company committed to a plan to reduce its employee headcount in order to reduce operating costs and increase margins. The plan

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

involves the termination of approximately 35 employees, mostly located in Europe. The restructuring costs related to this plan primarily consist of one-time termination benefits. This restructuring plan did not involve any non-cash components. Costs relating to restructuring activities recorded under this plan have been included in cost of sales, selling, general and administrative expenses and research and development expenses.

The following table sets forth changes in the Company’s restructuring liability relating to the foregoing plan during the first quarter of fiscal year 2009:

Fiscal Year 2007 Plan. During ~~the third quarter of~~ fiscal year 2007, the Company committed to a plan to combine and optimize the development and assembly of most of its ~~NMR~~nuclear resonance (“NMR”) and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies. As part of the plan, the Company is creating an information rich detection (“IRD”) center in Walnut Creek, California, where NMR operations ~~currently located in Palo Alto, California~~ are being integrated with mass spectrometry operations already located in Walnut Creek. The Company is investing in a new 45,000 square foot building and a substantial remodel of an existing building there to house the IRD center.

As a result of the plan, a number of employee positions have been or will be relocated or eliminated and certain facilities ~~have been or~~ will be consolidated. These actions primarily impact the Scientific Instruments segment and involve the elimination of between approximately 40 and 60 positions. ~~The Company expects these activities to be completed during fiscal year 2009.~~

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

Restructuring and other related costs associated with this plan include one-time termination benefits, retention payments, costs to relocate facilities (including decommissioning costs, moving costs and temporary facility/storage costs), accelerated depreciation of fixed assets to be disposed as a result of facilities actions and lease termination costs. Costs relating to restructuring activities recorded under this plan have been included in cost of sales, selling, general and administrative expenses and research and development expenses.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The following table sets forth changes in the Company’s restructuring liability relating to the foregoing plan during the first ~~second and third quarters~~quarter of fiscal year ~~2008:~~2009:


		Employee- Related			Facilities- Related			Total				Employee- Related			Facilities- Related			Total
(in thousands)
Balance at September 28, 2007		$	2,222		$	—		$	2,222
Charges to expense, net			453			761			1,214
Balance at October 3, 2008												$	1,840		$	551		$	2,391
Reversals of expense, net													(387	)		—			(387	)
Cash payments			(181	)		(77	)		(258	)			—			(38	)		(38	)
Foreign currency impacts and other adjustments			24			(20	)		4				(2	)		17			15

Balance at December 28, 2007			2,518			664			3,182
Charges to expense, net			51			—			51
Cash payments			(1,020	)		(44	)		(1,064	)
Foreign currency impacts and other adjustments			36			136			172

Balance at March 28, 2008			1,585			756			2,341
Charges to expense, net			294			—			294
Cash payments			(107	)		(64	)		(171	)
Foreign currency impacts and other adjustments			(4	)		(11	)		(15	)

Balance at June 27, 2008		$	1,768		$	681		$	2,449
Balance at January 2, 2009												$	1,451		$	530		$	1,981


Total expense since inception of plans
(in millions)
Restructuring expense	Restructuring expense							$	3.9		Restructuring expense							$	4.0

Other restructuring-related costs	Other restructuring-related costs							$	4.7		Other restructuring-related costs							$	6.2

The reversals of restructuring ~~charges~~expense of ~~$0.3 million and $1.6~~$0.4 million recorded during the fiscal quarter ~~and nine months~~ ended ~~June 27, 2008~~January 2, 2009 related to changes in estimates of certain employee termination ~~benefits and costs associated with the closure of leased facilities.~~benefits. The Company also incurred ~~$1.4 million and $2.7~~$0.8 million in other restructuring-related costs during the fiscal quarter ~~and nine months~~ ended ~~June 27, 2008, respectively.~~January 2, 2009. These costs were related to employee retention costs and facilities-related costs including decommissioning costs and non-cash charges for accelerated depreciation of assets to be disposed upon the closure of facilities.

Product Warranties. The Company’s products are generally subject to warranties. Liabilities for the estimated future costs of repair or replacement are established and charged to cost of sales at the time the related sale is recognized. The amount of liability to be recorded is based on management’s best estimates of future warranty costs after considering historical and projected product failure rates and product repair costs.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

Changes in the Company’s estimated liability for product warranty during the ~~nine months~~fiscal quarters ended ~~June 27, 2008~~January 2, 2009 and ~~June 29,~~December 28, 2007 follow:


	Nine Months Ended						Fiscal Quarter Ended
	June 27, 2008			June 29, 2007			January 2, 2009			December 28, 2007
(in thousands)
Beginning balance	$	12,454		$	11,042		$	13,867		$	12,454
Charges to costs and expenses		3,571			3,856			5,037			4,921
Warranty expenditures and other adjustments		(3,521	)		(3,433	)		(5,720	)		(4,849	)
Acquired warranty liabilities		1,098			—

Ending balance	$	13,602		$	11,465		$	13,184		$	12,526

Indemnification Obligations. Financial Accounting Standards Board (“FASB”) Interpretation No. (“FIN”) 45,Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, requires a guarantor to recognize a liability for and/or disclose obligations it has undertaken in relation to the issuance of the guarantee. Under this guidance, arrangements involving indemnification clauses are subject to the disclosure requirements of FIN 45 only.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The Company is subject to certain indemnification obligations to VMS (formerly VAI) and VSEA in connection with the Instruments business as conducted by VAI prior to the Distribution (described in Note 2). These indemnification obligations cover a variety of aspects of the Company’s business, including, but not limited to, employee, tax, intellectual property, litigation and environmental matters. Certain of the agreements containing these indemnification obligations are disclosed as exhibits to the Company’s Annual Report on Form 10-K. The estimated fair value of these indemnification obligations is not considered to be material.

The Company is subject to certain indemnification obligations to Jabil Circuit, Inc. (“Jabil”) in connection with the Company’s sale of its Electronics Manufacturing Business to Jabil. These indemnification obligations cover certain aspects of the Company’s conduct of the Electronics Manufacturing Business prior to its sale to Jabil, including, but not limited to, tax and environmental matters. The agreement containing these indemnification obligations is disclosed as an exhibit to the Company’s Annual Report on Form 10-K. The estimated fair value of these indemnification obligations is not considered to be material.

The Company’s By-Laws require it to indemnify its officers and directors, as well as those who act as directors and officers of other entities at the request of the Company, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to the Company. In addition, the Company has entered into separate indemnity agreements with each director and officer that provide for indemnification of these directors and officers under certain circumstances. The form of these indemnity agreements is disclosed as an exhibit to the Company’s Annual Report on Form 10-K. The indemnification obligations are more fully described in these indemnity agreements and the Company’s By-Laws. The Company purchases insurance to cover claims or a portion of any claims made against its directors and officers. Since a maximum obligation is not explicitly stated in the Company’s By-Laws or these indemnity agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot reasonably be estimated. Historically, the Company has not made payments related to these indemnification obligations and the estimated fair value of these indemnification obligations is not considered to be material.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

As is customary in the Company’s industry and as provided for in local law in the U.S. and other jurisdictions, many of the Company’s standard contracts provide remedies to customers and other third parties with whom the Company enters into contracts, such as defense, settlement or payment of judgment for intellectual property claims related to the use of its products. From time to time, the Company also agrees to indemnify customers, suppliers, contractors, lessors, lessees and others with whom it enters into contracts, against loss, expense and/or liability arising from various triggering events related to the sale and the use of the Company’s products and services, the use of their goods and services, the use of facilities and other matters covered by such contracts, usually up to a specified maximum amount. In addition, from time to time, the Company ~~sometimes~~ also agrees to indemnify these parties against claims related to undiscovered liabilities, additional product liability or environmental obligations. Claims made under such indemnification obligations have been insignificant and the estimated fair value of these indemnification obligations is not considered to be material.

Credit Facilities. The Company maintains relationships with banks in many countries from whom it sometimes obtains bank guarantees and short-term standby letters of credit. These guarantees and letters of credit relate primarily to advance payments and deposits made to the Company’s subsidiaries by customers for which separate liabilities are recorded in the unaudited condensed consolidated financial statements. As of ~~June 27, 2008,~~January 2, 2009, a total of ~~$23.2~~$20.5 million of these bank guarantees and letters of credit were outstanding. No amounts had been drawn by beneficiaries under these or any other outstanding guarantees or letters of credit as of that date.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Long-term Debt. As of ~~June 27,~~both January 2, 2009 and October 3, 2008, the Company had an $18.8 million term loan outstanding with a U.S. financial ~~institution. The balance outstanding under this term loan was $25.0 million~~institution at ~~September 28, 2007. As of both June 27, 2008 and September 28, 2007, the~~a fixed interest rate ~~on the term loan was~~of 6.7%. The term loan contains certain covenants that limit future borrowings and the payment of cash dividends and require the maintenance of certain levels of working capital and operating results. The Company was in compliance with all restrictive covenants of the term loan agreement at ~~June 27, 2008.~~January 2, 2009.

The following table summarizes future principal payments on borrowings under long-term debt outstanding as of ~~June 27, 2008:~~January 2, 2009:


	Fiscal Quarter Ending Oct. 3, 2008		Fiscal Years												Total		Nine Months Ending Oct. 2, 2009			Fiscal Years
			2009		2010		2011		2012		2013		Thereafter						2010			2011			2012			2013			2014			Thereafter			Total
(in thousands)
Long-term debt (including current portion)	$	—	$	—	$	6,250	$	—	$	6,250	$	—	$	6,250	$	18,750
Long-term debt																	$	—		$	6,250		$	—		$	6,250		$	—		$	6,250		$	—		$	18,750

~~VARIAN, INC. AND SUBSIDIARY COMPANIES~~Based upon rates currently available to the Company for debt with similar terms and remaining maturities, the carrying amount of long-term debt approximates the estimated fair value.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

Net Periodic Pension Cost. The components of net periodic pension cost relating to the Company’s defined benefit retirement plans follow:


	Fiscal Quarter Ended						Nine Months Ended						Fiscal Quarter Ended
	June 27, 2008			June 29, 2007			June 27, 2008			June 29, 2007			January 2, 2009			December 28, 2007
(in thousands)
Service cost	$	343		$	334		$	1,029		$	1,002		$	249		$	343
Interest cost		723			626			2,169			1,878			705			723
Expected return on plan assets		(653	)		(512	)		(1,959	)		(1,536	)		(570	)		(653	)
Amortization of prior service cost and actuarial gains and losses		—			111			—			333			17			—

Net periodic pension cost	$	413		$	559		$	1,239		$	1,677		$	401		$	413

Employer Contributions. During the fiscal quarter ~~and nine months~~ ended ~~June 27, 2008,~~January 2, 2009, the Company made contributions totaling $0.3 ~~million and $1.0~~ million to its defined benefit pension plans. The Company currently anticipates contributing an additional ~~$0.4~~$0.9 million to these plans in the ~~fourth quarter~~remaining nine months of fiscal year ~~2008.~~2009.

Environmental Matters. The Company’s operations are subject to various federal, state and local laws in the U.S. as well as laws in other countries regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. These regulations increase the costs and potential liabilities of the Company’s operations. However, the Company does not currently anticipate that its compliance with these regulations will have a material effect on the Company’s capital expenditures, earnings or competitive position.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The Company and VSEA are each obligated (under the terms of the Distribution described in Note 2) to indemnify VMS for one-third of certain costs (after adjusting for any insurance recoveries and tax benefits recognized or realized by VMS for such costs) relating to (a) environmental investigation, monitoring and/or remediation activities at certain facilities previously operated by VAI and third-party claims made in connection with environmental conditions at those facilities, and (b) U.S. Environmental Protection Agency or third-party claims alleging that VAI or VMS is a potentially responsible party under the Comprehensive Environmental Response Compensation and Liability Act of 1980, as amended (“CERCLA”) in connection with certain sites to which VAI allegedly shipped manufacturing waste for recycling, treatment or disposal (the “CERCLA sites”). With respect to the facilities formerly operated by VAI, VMS is overseeing the environmental investigation, monitoring and/or remediation activities, in most cases under the direction of or in consultation with federal, state and/or local agencies, and handling third-party claims. VMS is also handling claims relating to the CERCLA sites. The Company is also undertaking environmental investigation and/or monitoring activities at one of its facilities under the direction of or in consultation with governmental agencies.

Various uncertainties make it difficult to estimate future costs for certain of these environmental-related activities, specifically external legal expenses, VMS’ internal oversight costs, third-party claims and a former VAI facility where the likelihood and scope of further environmental-related activities are difficult to assess. As of ~~June 27, 2008,~~January 2, 2009, it was nonetheless estimated that the Company’s future exposure for these environmental-related costs ranged in the aggregate from $1.1 million to $2.6 million. The time frame over which these costs are expected to be incurred varies with each type of cost, ranging up to approximately 2230 years as of ~~June 27, 2008.~~

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

January 2, 2009. No amount in the foregoing range of estimated future costs is discounted, and no amount in the range is believed to be more probable of being incurred than any other amount in such range. The Company therefore had an accrual of $1.1 million as of ~~June 27, 2008~~January 2, 2009 for these future environmental-related costs.

Sufficient knowledge has been gained to be able to better estimate other costs for future environmental-related activities. As of ~~June 27, 2008,~~January 2, 2009, it was estimated that the Company’s future costs for these environmental-related activities ranged in the aggregate from ~~$2.9~~$2.2 million to ~~$12.8~~$13.1 million. The time frame over which these costs are expected to be incurred varies, ranging up to approximately 2230 years as of ~~June 27, 2008.~~January 2, 2009. As to each of these ranges of cost estimates, it was determined that a particular amount within the range was a better estimate than any other amount within the range. Together, these amounts totaled ~~$5.8~~$5.7 million at ~~June 27, 2008.~~January 2, 2009. Because both the amount and timing of the recurring portion of these costs were reliably determinable, that portion is discounted at 4%, net of inflation. The Company therefore had an accrual of $4.1 million as of ~~June 27, 2008,~~January 2, 2009, which represents its best estimate of these future environmental-related costs after discounting estimated recurring future costs. This accrual is in addition to the $1.1 million described in the preceding paragraph.

The Company has not reduced any environmental-related liability in anticipation of recoveries from third parties. However, an insurance company has agreed to pay a portion of certain of VAI’s (now VMS’) future environmental-related costs, for which the Company has an indemnification obligation, and the Company therefore has a long-term receivable of $1.0 million (discounted at 4%, net of inflation) in ~~other~~Other assets as of ~~June 27, 2008,~~January 2, 2009, for the Company’s share of that insurance recovery.

The Company believes that its reserves for the foregoing and other environmental-related matters are adequate, but as the scope of its obligation becomes more clearly defined, these reserves may be modified and related charges against or credits to earnings may be made. Although any ultimate liability arising from environmental-related matters could result in significant expenditures that, if aggregated and assumed to occur within a single fiscal year, would be material to the Company’s financial statements, the likelihood of such occurrence is considered remote. Based on information currently available and its best assessment of the ultimate

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

amount and timing of environmental-related events, the Company believes that the costs of environmental-related matters are not reasonably likely to have a material adverse effect on the Company’s financial condition or results of operations.

Legal Proceedings. The Company is involved in pending legal proceedings that are ordinary, routine and incidental to its business. While the ultimate outcome of these legal matters is not determinable, the Company believes that these matters are not reasonably likely to have a material adverse effect on the Company’s financial condition or results of operations.

Share-Based Compensation Expense. ~~The Company accounts for share-based awards in accordance with the provisions of SFAS 123(R),~~~~Share-Based Payment~~.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

The following table summarizes the amount of share-based compensation expense by award type as well as the effect of this expense on ~~net earnings~~income tax expense and net ~~earnings per share:~~earnings:


	Fiscal Quarter Ended						Nine Months Ended						Fiscal Quarter Ended
	June 27, 2008			June 29, 2007			June 27, 2008			June 29, 2007			January 2, 2009			December 28, 2007
(in thousands, except per share amounts)
Share-based compensation expense by award type:
Employee and non-employee director stock options	$	(1,359	)	$	(1,424	)	$	(4,150	)	$	(5,404	)	$	(1,365	)	$	(968	)
Employee stock purchase plan		(224	)		(219	)		(787	)		(722	)		(336	)		(310	)
Restricted (nonvested) stock⁽¹⁾		(802	)		(533	)		(2,045	)		(1,639	)
Non-employee director stock units		—			—			(225	)		(125	)
Restricted (nonvested) stock														(665	)		(441	)

Total share-based compensation expense (effect on earnings before income taxes)		(2,385	)		(2,176	)		(7,207	)		(7,890	)		(2,366	)		(1,719	)
Effect on income tax expense		744			794			2,070			2,879			773			564

Effect on net earnings	$	(1,641	)	$	(1,382	)	$	(5,137	)	$	(5,011	)	$	(1,593	)	$	(1,155	)


Effect on net earnings per share:
Basic	$	(0.06	)	$	(0.05	)	$	(0.17	)	$	(0.16	)

Diluted	$	(0.06	)	$	(0.04	)	$	(0.17	)	$	(0.16	)

Share-based compensation expense included in the preceding table related to restricted (non-vested) stock includes $0.1 million in both the fiscal quarter ended January 2, 2009 and the fiscal quarter ended December 28, 2007, related to restricted stock granted in connection with the Company’s fiscal year 2007 restructuring plan.

Share-based compensation expense has been included in the Company’s unaudited condensed consolidated statement of earnings as follows:


	Fiscal Quarter Ended				Nine Months Ended				Fiscal Quarter Ended
	June 27, 2008		June 29, 2007		June 27, 2008		June 29, 2007		January 2, 2009		December 28, 2007
(in thousands)
Cost of sales	$	106	$	103	$	338	$	322	$	133	$	124
Selling, general and administrative		2,164		1,936		6,503		7,177		2,119		1,461
Research and development		115		137		366		391		114		134

Total	$	2,385	$	2,176	$	7,207	$	7,890	$	2,366	$	1,719

Stock Options.Under the Omnibus Stock Plan (“OSP”), the Company periodically grants stock options to officers, directors and employees. The exercise price for stock options granted under the OSP may not be less than 100% of the fair market value at the date of the grant. Options granted are exercisable at the times and on

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

the terms established by the Compensation Committee, but not later than ten years after the date of grant (except in the event of death, after which an option is exercisable for three years). Options granted generally become exercisable in cumulative installments of one-third each year commencing one year following the date of grant.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

The following table summarizes stock option activity under the OSP for the ~~nine months~~fiscal quarter ended ~~June 27, 2008:~~January 2, 2009:


	Shares		Weighted Average Exercise Price		Aggregate Grant Date Fair Value ⁽¹⁾		Shares		Weighted Average Exercise Price		Aggregate Grant Date Fair Value ⁽¹⁾
	(in thousands)				(in millions)		(in thousands)				(in millions)
Outstanding at September 28, 2007	1,783		$	38.43
Outstanding at October 3, 2008							1,660		$	44.21
Granted	288		$	67.53	$	5.5	314		$	35.91	$	3.4
Exercised	(360	)	$	35.26			(1	)	$	9.50
Cancelled or expired	(7	)	$	56.97			(23	)	$	43.90

Outstanding at June 27, 2008	1,704		$	43.95
Outstanding at January 2, 2009							1,950		$	42.88

As of ~~June 27, 2008,~~January 2, 2009, the unrecognized share-based compensation ~~expense~~balance related to stock options was ~~$5.8~~$6.6 million. This amount will be recognized as expense using the straight-line attribution method over a weighted-average amortization period of ~~1.2~~1.4 years.

Restricted (Nonvested) Stock.Under the OSP, the Company also periodically grants restricted (nonvested) common stock to employees. Such grants are valued ~~using the quoted market value of the underlying common stock~~ as of the grant date. ~~The fair value of these shares is then~~These amounts are recognized by the Company as share-based compensation expense ratably over their respective vesting periods, which range from one to three years.

The following table summarizes restricted (nonvested) common stock activity under the OSP for the ~~nine months~~fiscal quarter ended ~~June 27, 2008:~~January 2, 2009:


	Shares		Weighted Average Grant Date Fair Value		Aggregate Grant Date Fair Value		Shares		Weighted Average Grant Date Fair Value		Aggregate Grant Date Fair Value
	(in thousands)				(in millions)		(in thousands)				(in millions)
Outstanding and unvested at September 28, 2007	111		$	43.92
Outstanding and unvested at October 3, 2008							105		$	54.51
Granted	42		$	69.44	$	2.9	17		$	35.97	$	0.6
Vested⁽¹⁾	(50	)	$	37.48			(53	)	$	49.83
Forfeited							(1	)	$	55.50

Outstanding and unvested at June 27, 2008	103		$	57.45
Outstanding and unvested at January 2, 2009							68		$	53.50

As of ~~June 27, 2008,~~January 2, 2009, there was a total of ~~$2.7~~$1.9 million in unrecognized share-based compensation expense related to restricted stock granted under the OSP. This expense will be recognized over a weighted-average amortization period of ~~1.3~~1.4 years.

~~Non-Employee Director Stock Units~~. Under the terms of the OSP, on the first business day following each annual meeting of the Company’s stockholders, each person then serving as a non-employee director is automatically granted stock units having an initial value of $45,000 (beginning in fiscal year 2008) and $25,000 (prior to fiscal year 2008). The stock units will vest upon termination of the director’s service on the Board of Directors and will then be satisfied by issuance of shares of the Company’s common stock. Each non-employee director who holds stock units will not have rights as a stockholder with respect to the shares issuable thereunder

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

until such shares are paid out. The stock units are not transferable, except to the non-employee director’s designated beneficiary or estate in the event of his or her death. During the nine months ended June 27, 2008 and June 29, 2007, the Company granted stock units with an aggregate value of $225,000 and $125,000, respectively, to non-employee members of its Board of Directors (of which there were five) and recognized the total value as share-based compensation expense at the time of grant.

Employee Stock Purchase Plan.During the fiscal ~~quarter~~quarters ended January 2, 2009 and ~~nine months ended June 27, 2008,~~December 28, 2007, employees purchased approximately 27,100 shares for $0.9 million and 20,000 shares for ~~$1.0 million and 61,000 shares for $3.1~~$0.9 million, respectively, under the Company’s Employee Stock Purchase Plan (“ESPP”). ~~During the fiscal quarter and nine months ended June 29, 2007, employees purchased approximately 25,000 shares for $0.9 million and 79,000 shares for $2.9 million, respectively.~~ As of ~~June 27, 2008,~~January 2, 2009, a total of approximately ~~207,000~~161,000 shares remained available for issuance under the ESPP.

Stock Repurchase Programs. In February 2008, the Company’s Board of Directors approved a ~~new~~ stock repurchase program under which the Company is authorized to utilize up to $100 million to repurchase shares of its common stock. This repurchase program is effective through December 31, 2009. During the ~~nine months~~fiscal quarter ended ~~June 27, 2008,~~January 2, 2009, the Company ~~repurchased and retired 567,000~~did not repurchase any shares of its common stock under this ~~authorization at an aggregate cost of $30.5 million.~~authorization. As of ~~June 27, 2008,~~January 2, 2009, the Company had remaining authorization to repurchase ~~$69.5~~$44.6 million of its common stock under this program.

In January 2007, the Company’s Board of Directors approved a stock repurchase program under which the Company was authorized to utilize up to $100 million to repurchase shares of its common stock. This repurchase program is effective through December 31, 2008. During the nine months ended June 27, 2008, the Company repurchased and retired 876,000 shares under this authorization at an aggregate cost of $50.4 million, which completed this repurchase program.

Other Stock Repurchases.During the ~~nine months~~fiscal quarter ended ~~June 27, 2008~~January 2, 2009, the Company repurchased and retired ~~14,000~~8,000 shares tendered to it by employees in settlement of employee tax withholding obligations due from those employees upon the vesting of restricted stock.

~~The Company has equity investments in privately held companies which, because of its ownership interest and other factors, are carried at cost. The Company monitors these investments for impairment.~~

During the second quarter of fiscal year 2008, the Company became aware of information which raised substantial doubt about the ability of a small, privately held company in which the Company holds a cost-method equity investment to continue as a going concern. Based on this information, the Company determined that the fair value of its investment had declined and that the decline was other-than-temporary. As a result, the Company wrote off the entire $3.0 million carrying value of its investment via an impairment charge in the period.

~~Effective September 29, 2007, the Company adopted FIN 48,~~~~Accounting for Uncertainty in Income Taxes – An Interpretation of FASB Statement No 109~~, which addresses accounting for, and disclosure of, uncertain tax positions. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As a result of the adoption of FIN 48, the Company reduced its liability for unrecognized tax benefits and increased deferred tax

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

assets by $2.4 million and $0.6 million, respectively. These adjustments were aggregated and accounted for as a cumulative effect of a change in accounting principle, which resulted in an increase to retained earnings of $3.0 million. The total amount of unrecognized tax benefits excluding interest thereon as of the date of adoption was $6.9 million, substantially all of which would impact the effective tax rate if realized. The Company’s policy to include interest and penalties related to income taxes within income tax expense did not change as a result of implementing FIN 48. As of the date of adoption of FIN 48, the Company had accrued $0.7 million in income taxes payable for the payment of interest and penalties related to unrecognized tax benefits.

The Company’s U.S. federal, state and local ~~income tax returns~~ and ~~non-U.S.~~foreign income tax returns are subject to audit by relevant tax authorities. The Company’s income tax reporting periods beginning after fiscal year 2004 for the U.S. and after fiscal year 2001 for the Company’s major non-U.S. jurisdictions remain generally open to audit by relevant tax authorities.

During the fiscal quarter ended June 27, 2008, total unrecognized tax benefits were decreased by $0.6 million due to the lapse of certain statutes of limitations in the period which resulted in a $1.0 million reduction, which was partially offset by additions for current-year unrecognized tax benefits. During the nine months ended June 27, 2008, total unrecognized tax benefits were decreased by $1.5 million due to the lapse of certain statutes of limitations in the period which resulted in a $2.3 million reduction, partially offset by additions for current-year unrecognized tax benefits. These net decreases resulted in corresponding tax benefits in the fiscal quarter and nine months ended June 27, 2008, respectively.

At June 27, 2008, the total amount of unrecognized tax benefits was $5.4 million, substantially all of which would impact the effective tax rate if realized. Income taxes payable at June 27, 2008 included accrued interest and penalties of $0.5 million. Although the timing and outcome of income tax audits is highly uncertain, itthe Company has reasonably recorded liabilities for associated unrecognized tax benefits. It is possible that certain unrecognized tax benefits could decrease by $1.1 million in the next twelve months due to the lapse of certain statutes of limitation and result in a reduction in ~~the annual effective~~income tax ~~rate of up to 1%.~~expense. Any such reduction could be impacted by other changes in ~~other~~ unrecognized tax benefits.

Basic earnings per share are calculated based on net earnings and the weighted-average number of shares of common stock outstanding during the reported period. Diluted earnings per share are calculated similarly, except that the weighted-average number of common shares outstanding during the period ~~are~~is increased by the number of additional shares of common stock that would have been outstanding if the dilutive potential shares of common stock had been issued. The dilutive effect of potential common stock (including outstanding stock options, unvested restricted stock and non-employee director stock units) is reflected in diluted earnings per share by application of the treasury stock method, which includes consideration of share-based compensation and the tax benefit thereon as required by SFAS 123(R).

For the fiscal ~~quarter~~quarters ended January 2, 2009 and ~~nine months ended June 27, 2008,~~December 28, 2007, options to purchase ~~282,000~~1,790,000 and 256,000 shares, respectively, were excluded from the calculation of diluted earnings per share as their effect was anti-dilutive. ~~For the fiscal quarter and nine months ended June 29, 2007, options~~

A reconciliation of weighted-average basic shares outstanding to ~~purchase 5,000 and 31,000~~weighted-average diluted shares ~~respectively, were excluded from the calculation of diluted earnings per share as their effect was anti-dilutive.~~outstanding follows:

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

~~A reconciliation of weighted-average basic shares outstanding to weighted-average diluted shares outstanding follows:~~

For financial reporting purposes, the Company’s operations are grouped into two business segments: Scientific Instruments and Vacuum Technologies. The Scientific Instruments segment designs, develops, manufactures, markets, sells and services equipment and related software, consumable products, accessories and services for a broad range of life science, environmental, energy, and ~~industrial (which includes environmental, food~~applied research and ~~energy)~~other applications requiring identification, quantification and analysis of the composition or structure of liquids, solids or gases. The Vacuum Technologies segment designs, develops, manufactures, markets, sells and services vacuum products and related accessories and services used to create, contain, control, measure and test vacuum environments in a broad range of life science, industrial and ~~industrial~~other applications requiring ultra-clean or high-vacuum environments. These segments were determined in accordance with SFAS 131,Disclosures about Segments of an Enterprise and Related Information.

General corporate costs include shared costs of legal, tax, accounting, treasury, insurance and certain other management costs. A portion of the indirect and common costs has been allocated to the segments through the use of estimates. Also, transactions between segments are accounted for at cost and are not included in sales. Accordingly, the following information is provided for purposes of achieving an understanding of operations, but might not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies might not be meaningful.

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

In September 2006, the FASB issued SFAS 157, Fair Value Measurements,~~. SFAS 157~~ which defines fair value, establishes a framework for measuring fair value ~~in generally accepted accounting principles~~ and expands disclosures about fair value measurements. SFAS 157 applies to previous accounting pronouncements that require or permit fair value measurements. SFAS 157 is effective for fiscal years beginning after November 15, 2007, with certain exceptions which are described below. In ~~February 2008, the FASB issued FASB Staff Position (“FSP”) 157-1,~~ Application of FASB Statement No. 157 to FASB Statement No. 13 and Other Accounting Pronouncements That Address Fair Value Measurements for Purposes of Lease Classification or Measurement under Statement 13 ~~(“FSP 157-1”), which amends SFAS 157 to exclude certain leasing transaction from its scope. Also in~~ February 2008, the FASB issued FSP 157-2,Effective Date of FASB Statement No. 157,which delays the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities to fiscal years beginning after November 15, 2008, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). The Company adopted SFAS 157 effective October 4, 2008 with the exception of the application of the statement to nonrecurring nonfinancial assets and nonfinancial liabilities (see Note 4). The Company does not expect the adoption of ~~SFAS 157~~the provisions deferred by FSP 157-2 to have a material impact on its financial condition or results of operations.

~~In February 2007, the FASB issued SFAS 159,~~~~The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement 115~~, which provides companies with an option to measure eligible financial assets and liabilities in their entirety at fair value. The fair value option may be applied instrument by instrument, and may be applied only to entire instruments. If a company elects the fair value option for an eligible item, changes in the item’s fair value must be reported as unrealized gains and losses in earnings at each subsequent reporting date. SFAS 159 is effective for fiscal years beginning after November 15, 2007. The Company is evaluating the options provided under SFAS 159 and their potential impact on its financial condition and results of operations if implemented.

In December 2007, the FASB issued SFAS 141 (revised 2007),Business Combinations, (“SFAS 141(R)”). SFAS 141(R) retains the fundamental requirements of the original pronouncement requiring that the purchase

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

method be used for all business combinations but also provides revised guidance for recognizing and measuring identifiable assets and goodwill acquired, liabilities assumed, and any noncontrolling interest in the acquiree. It also requires the recognition of assets acquired and liabilities assumed arising from contingencies, the capitalization of in-process research and development at fair value, and the expensing of acquisition-related costs as incurred.SFAS 141(R) also requires that certain tax contingencies and adjustments to valuation allowances related to business combinations, which previously were adjusted to goodwill, must be adjusted to income tax expense, regardless of the date of the original business combination. SFAS 141(R) is effective for fiscal years beginning after December 15, 2008. The Company ~~is currently evaluating the requirements of SFAS 141(R) and~~ does not expect its adoption in the first quarter of

~~NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)~~

fiscal year 2010 to have a material impact on the Company’s financial condition or results of operations. However, in the event that the Company completes acquisitions subsequent to its adoption of SFAS 141(R), the application of its provisions will likely have a material impact on the Company’s results of operations, although the Company is not currently able to estimate that impact.

In December 2007, the FASB issued SFAS 160,Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51. SFAS 160 requires that ownership interests in subsidiaries held by parties other than the parent and the amount of consolidated net income be clearly identified, labeled and presented in the consolidated financial statements. It also requires once a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary be initially measured at fair value. Sufficient disclosures are required to clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS 160 is effective for fiscal years beginning after December 15, 2008, and requires retroactive adoption of the presentation and disclosure requirements for existing minority interests. All other requirements are applied prospectively. The Company does not expect the adoption of SFAS 160 to have a material impact on its financial condition or results of operations.

In March 2008, the FASB issued SFAS 161,Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133,which requires additional disclosures about the objectives and strategies of ~~the~~ derivative instruments and hedging activities, the method of accounting for such instruments under SFAS 133 and its related interpretations, and a tabular disclosure of the effects of such instruments and related hedged items on the Company’s financial condition and results of operations. SFAS 161 is effective for fiscal years beginning after November 15, 2008. The Company does not expect the adoption of SFAS 161 to have a material impact on its financial condition or results of operations.

In April 2008, the FASB issued FSP 142-3,Determination of the Useful Life of Intangible Assets, which amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset. The intent of FSP 142-3 is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142,Goodwill and Other Intangible Assets, and the period of expected cash flows used to measure the fair value of the asset under SFAS 141(R),Business Combinations, and other accounting literature. FSP 142-3 is effective for fiscal years beginning after December 15, 2008, and must be applied prospectively to intangible assets acquired after the effective date. Early adoption is prohibited. Given that FSP 142-3 applies to intangible assets acquired after the effective date, the Company isdoes not ~~yet able to determine whether~~expect its adoption ~~will~~to have a material impact on its financial condition or results of operations.

In December 2008, the FASB issued FSP 132(R)-1,Employers’ Disclosures about Postretirement Benefit Plan Assets. FSP 132(R)-1 amends SFAS 132 (revised 2003),Employers’ Disclosures about Pensions and Other Postretirement Benefits, to provide guidance on an employer’s disclosures about plan assets of a defined benefit pension or other postretirement plan. This FSP is effective for fiscal years ending after December 15, 2009. The Company does not expect the adoption of FSP 132(R)-1 to have a material impact on its financial condition or results of operations.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

During the second quarter of fiscal year 2009, the Company committed to a plan to reduce its cost structure, primarily through headcount reductions, due to continuing uncertainty in the global economic environment. The plan primarily involved the elimination of approximately 240 regular employee and 80 temporary positions (primarily in North America and Europe and, to a lesser extent, Asia Pacific and Latin America) in both the Scientific Instruments and Vacuum Technologies segments. In addition, the plan included the closure of one small R&D/manufacturing facility in North America (Lake Forest, California) and two sales offices in Europe (Sweden and Switzerland).

Restructuring and other related costs expected to be incurred in connection with this plan are currently estimated to be between $8.5 million and $10.5 million, of which between $8.0 million and $9.5 million is expected to impact the Scientific Instruments segment and between $0.5 million and $1.0 million is expected to impact the Vacuum Technologies segment. The restructuring costs are expected to include one-time termination benefits for employees whose positions are being eliminated of between $7.5 million and $9.0 million and lease termination costs of between $0.1 million and $0.2 million (including future lease payments on vacated facilities). Other restructuring-related costs are expected to include employee retention and relocation costs of between $0.3 million and $1.0 million and facility-related relocation costs and accelerated depreciation of fixed assets to be disposed upon the closure of facilities of between $0.1 million and $0.3 million. These costs will be recorded and included in cost of sales, selling, general and administrative expenses and research and development expenses.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Throughout this Report, and particularly in thisItem 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations, there are forward-looking statements that are based upon our current expectations, estimates and projections and that reflect our beliefs and assumptions based upon information available to us at the date of this Report. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and other similar terms. These forward-looking statements include (but are not limited to) those relating to the timing and amount of anticipated restructuring and other related costs and related cost savings as well as anticipated capital expenditures in fiscal year ~~2008.~~2009.

We caution investors that forward-looking statements are only our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements. Some of the important factors that could cause our results to differ are discussed inItem 1A—Risk Factors in our Annual Report on Form 10-K for the fiscal year ended ~~September 28, 2007.~~October 3, 2008. We encourage you to read that section carefully.

Other risks and uncertainties that could cause actual results to differ materially from those in our forward-looking statements include, but are not limited to, the following: when and how quickly global economic conditions improve, and whether conditions worsen before they improve, whether we will succeed in new product development, release, commercialization, performance and acceptance; whether we can achieve continued growth in sales for ~~industrial~~life science, environmental, energy and/or ~~life science~~applied research and other applications; whether we can achieve ~~continued~~ sales growth in Europe, ~~and~~North America, Asia Pacific and/or ~~stronger growth in sales in the U.S.;~~Latin America; risks arising from the timing of shipments, installations and the recognition of revenues on certain ~~magnet-based~~research products, including nuclear magnetic resonance (“NMR”) spectroscopy systems, magnetic resonance (“MR”) imaging systems and fourier transform mass spectrometry (“FTMS”) systems and superconducting magnets; the impact of shifting product mix on profit margins; competitive products and pricing; economic conditions in our various product and geographic markets; whether we will see continued and timely delivery of key raw materials and components by suppliers; foreign currency fluctuations that could adversely impact revenue growth ~~and~~and/or earnings; whether we will see continued investment in capital equipment, in particular given the global liquidity and credit ~~concerns;~~crisis; whether we will see reduced demand from customers that operate in cyclical industries; whether the global liquidity and credit crisis will impact the collectability of accounts receivable from our customers; the impact of any delay or reduction in government funding for research; our ability to successfully evaluate, negotiate and integrate ~~acquisitions;~~acquisitions, in particular given the greater difficulty to borrow in the current credit environment; the actual costs, timing and benefits of restructuring activities (such as the employee reductions and other actions announced on January 16, 2009 and our Northern California ~~facilities~~operations consolidation) and other efficiency improvement activities (such as our global procurement, lower-cost manufacturing and outsourcing initiatives); variability in our effective income tax rate (due to factors including the timing and amount of discrete tax events and changes to unrecognized tax benefits); the timing and amount of share-based compensation; and other risks detailed from time to time in our filings with the U.S. Securities and Exchange Commission (the “SEC”). We undertake no special obligation to update any forward-looking statements, whether in response to new information, future events or otherwise.

~~Third~~First Quarter of Fiscal Year ~~2008~~2009 Compared to ~~Third~~First Quarter of Fiscal Year ~~2007~~2008

For financial reporting purposes, our operations are grouped into two reportable business segments: Scientific Instruments and Vacuum Technologies. The following table presents comparisons of our sales and operating earnings for each of those segments and in total for the ~~third quarters~~first quarter of fiscal years ~~2008~~2009 and ~~2007:~~2008:


	Fiscal Quarter Ended															Fiscal Quarter Ended										Increase (Decrease)
	June 27, 2008					June 29, 2007					Increase (Decrease)					January 2, 2009					December 28, 2007					Increase (Decrease)
	$			% of Sales		$			% of Sales		$			%		$			% of Sales		$			% of Sales		$			%
(dollars in millions)
Sales by Segment:
Scientific Instruments	$	200.7		82.1	%	$	187.0		82.3	%	$	13.7		7.3	%	$	171.8		82.5	%	$	197.0		83.0	%	$	(25.2	)	(12.8	)%
Vacuum Technologies		43.7		17.9			40.1		17.7			3.6		9.0			36.4		17.5			40.4		17.0			(4.0	)	(9.9	)

Total company	$	244.4		100.0	%	$	227.1		100.0	%	$	17.3		7.6	%	$	208.2		100.0	%	$	237.4		100.0	%	$	(29.2	)	(12.3	)%


Operating Earnings by Segment:
Scientific Instruments	$	12.2		6.1	%	$	17.4		9.3	%	$	(5.2	)	(29.9	)%	$	16.4		9.6	%	$	19.8		10.1	%	$	(3.4	)	(17.1	)%
Vacuum Technologies		7.8		17.7			7.8		19.5			—		—			7.1		19.3			7.7		19.1			(0.6	)	(9.0	)

Total segments		20.0		8.2			25.2		11.1			(5.2	)	(20.9	)		23.5		11.3			27.5		11.6			(4.0	)	(14.8	)
General corporate		(2.6	)	(1.1	)		(4.5	)	(2.0	)		1.9		43.6			(3.6	)	(1.7	)		(3.4	)	(1.4	)		(0.2	)	(5.2	)

Total company	$	17.4		7.1	%	$	20.7		9.1	%	$	(3.3	)	(15.9	)%	$	19.9		9.6	%	$	24.1		10.2	%	$	(4.2	)	(17.6	)%

Scientific Instruments. The ~~increase~~decrease in Scientific Instruments sales was primarily attributable to ~~higher~~lower sales volume of our ~~analytical instruments~~research products (in particular, NMR and ~~consumable~~imaging systems), products ~~partially offset by lower sales~~for traditional energy and raw material applications, and the negative impact of ~~magnet-based products (primarily due to delayed deliveries and installations of a few large systems). The weaker~~the stronger U.S. dollar on reported revenues. The timing of research products sales is often impacted by factors such as laboratory readiness and ~~recent acquisitions also had a positive impact on Scientific Instruments~~access to customer sites, duration of installations and availability of key components and installation personnel. The lower volume of research product sales ~~growth. Sales increased for both industrial (which includes environmental, food and energy) and life science applications.~~

~~Scientific Instruments revenues for~~in the ~~third~~first quarter of fiscal year ~~2007 do not include sales~~2009 was primarily due to delays due to some of these factors, compounded by the shorter working month and customer shutdowns in December 2008. Sales from ~~acquisitions completed since the third quarter of fiscal year 2007, primarily Oxford Diffraction Limited (“Oxford Diffraction”), which was~~businesses acquired in April 2008, and the business of Analogix, Inc. (the “Analogix Business”), which was acquired in November 2007. In the aggregate, these acquisitions contributed approximately 1% to Scientific Instruments sales growth in the third quarter of fiscal year 2008 ~~compared to the third quarter of fiscal year 2007.~~positively impacted reported sales by approximately 2%.

Scientific Instruments operating earnings for the ~~third~~first quarter of fiscal year 2009 included acquisition-related intangible amortization of $2.1 million and restructuring and other related costs of $1.6 million. In comparison, Scientific Instruments operating earnings for the first quarter of fiscal year 2008 included ~~an acquisition-related in-process research and development charge of $1.5 million,~~ acquisition-related intangible amortization of ~~$2.4~~$1.8 million, amortization of ~~$0.6~~$0.5 million related to inventory written up to fair value primarily in connection with the acquisition of ~~Oxford Diffraction,~~IonSpec Corporation (“IonSpec”) and restructuring and other related costs of $1.7 million and share-based compensation expense of $0.9 million. In comparison, Scientific Instruments operating earnings for the third quarter of fiscal year 2007 included acquisition-related intangible amortization of $1.8 million, restructuring and other related costs of $2.9 million and share-based compensation expense of $0.7$2.0 million. Excluding the impact of these items, ~~the decrease in~~ operating earnings decreased as a percentage of sales ~~was attributable to higher transition costs related~~due to the ~~relocation~~negative impact of ~~manufacturing activities for certain products,~~lower sales volume, partially offset by the ~~continued weakening~~positive impact of efficiency improvements implemented in recent years and the stronger U.S. dollar (which was ~~favorable~~unfavorable to reported sales but ~~unfavorable~~favorable to reported operating margins) ~~and, to a lesser extent, the transition effect of acquisitions completed in the quarter.~~.

~~We expect our initiatives to relocate manufacturing activities for certain products to have some residual negative impact on revenue and profitability in the fourth quarter of fiscal 2008.~~

Vacuum Technologies. The ~~increase~~decrease in Vacuum Technologies sales was driven by ~~higher~~lower sales volume ~~across a broad range~~of products for industrial applications and by the negative impact of the ~~segment’s products and services. The weaker~~stronger U.S. dollar ~~also had a positive impact~~ on ~~Vacuum Technologies sales growth. Sales increased for both industrial and life science applications.~~reported revenues.

Vacuum Technologies operating earnings for the ~~third quarters~~first quarter of fiscal ~~years 2008 and 2007 include~~year 2009 included the impact of ~~share-based compensation expense~~restructuring and other related costs of ~~$0.2 million and~~ $0.1 ~~million, respectively.~~million. Excluding the impact of ~~these items,~~this item, the ~~decrease~~increase in Vacuum

Technologies operating earnings as a percentage of sales iswas primarily due to the ~~result~~positive impact of efficiency improvements implemented in recent years and the ~~continued weakening of the~~stronger U.S. dollar, ~~which was only~~ partially offset by the ~~positive~~negative impact of lower sales ~~volume leverage in the third quarter of fiscal year 2008.~~volume.

The following table presents comparisons of our sales and other selected consolidated financial results for the ~~third quarters~~first quarter of fiscal years ~~2008~~2009 and ~~2007:~~2008:


	Fiscal Quarter Ended															Fiscal Quarter Ended										Increase (Decrease)
	June 27, 2008					June 29, 2007					Increase (Decrease)					January 2, 2009					December 28, 2007					Increase (Decrease)
	$			% of Sales		$			% of Sales		$			%		$			% of Sales		$			% of Sales		$			%
(dollars in millions, except per share data)
Sales	$	244.4		100.0	%	$	227.1		100.0	%	$	17.3		7.6	%
Sales:																$	208.2		100.0	%	$	237.4		100.0	%	$	(29.2	)	(12.3	)%

Gross profit		106.2		43.4			101.9		44.9			4.3		4.2			95.3		45.8			107.3		45.2			(12.0	)	(11.2	)

Operating expenses:
Selling, general and administrative		68.8		28.1			64.3		28.4	%		4.5		6.9			60.9		29.2			66.0		27.8	%		(5.1	)	(7.7	)
Research and development		18.5		7.6			16.9		7.4			1.6		9.7			14.5		7.0			17.2		7.2			(2.7	)	(15.5	)
Purchased in-process research and development		1.5		0.6			—		—			1.5		100.0

Total operating expenses		88.8		36.3			81.2		35.8			7.6		9.3			75.4		36.2			83.2		35.0			(7.8	)	(9.3	)

Operating earnings		17.4		7.1			20.7		9.1			(3.3	)	(15.9	)		19.9		9.6			24.1		10.2			(4.2	)	(17.6	)
Interest income		1.2		0.5			1.6		0.7			(0.4	)	(26.0	)		0.5		0.3			1.9		0.8			(1.4	)	(69.7	)
Interest expense		(0.4	)	(0.2	)		(0.4	)	(0.2	)		—		14.0			(0.3	)	(0.2	)		(0.4	)	(0.2	)		0.1		28.5
Income tax expense		(6.8	)	(2.8	)		(7.3	)	(3.2	)		0.5		6.4			(7.1	)	(3.4	)		(8.0	)	(3.4	)		0.9		11.6

Net earnings	$	11.4		4.6	%	$	14.6		6.4	%	$	(3.2	)	(21.9	)%	$	13.0		6.3	%	$	17.6		7.4	%	$	(4.6	)	(25.8	)%

Net earnings per diluted share	$	0.38				$	0.47				$	(0.09	)			$	0.45				$	0.57				$	(0.12	)

Sales. As discussed under the headingSegment Results above, sales by our Scientific Instruments and Vacuum Technologies segments in the ~~third~~first quarter of fiscal year ~~2008 increased~~2009 decreased by ~~7.3%~~12.8% and ~~9.0%~~9.9%, respectively, compared to the prior-year quarter. ~~The growth~~On a consolidated basis, sales declined 12.3% in ~~consolidated sales was broad-based, with increases in sales of products for both industrial (which includes environmental, food and energy) and life science applications. Recent acquisitions and~~ the weaker U.S. dollar also had a positive effect on the reported sales increases, while delayed deliveries and installations of a few large magnet-based products had a negative effect. Sales from acquisitions completed since the thirdfirst quarter of fiscal year ~~2007 contributed approximately 1%~~2009. This decrease was primarily due to ~~consolidated~~lower sales ~~growth~~of research products, but also reflects a decline in the ~~third quarter~~sales volume of certain vacuum and analytical products. Reported sales were also negatively impacted by the stronger U.S. dollar, which strengthened approximately 5% on a weighted-average basis compared to currencies in which we sell products and services. Sales from businesses acquired in fiscal year 2008 ~~compared to the third quarter of fiscal year 2007.~~positively impacted reported sales by approximately 2%.

For geographic reporting purposes, we use four regions—North America (excluding Mexico), Europe (including the Middle East and Africa), Asia Pacific (including India) and Latin America (including Mexico). Sales by geographic region in the ~~third~~first quarters of fiscal years ~~2008~~2009 and ~~2007~~2008 were as ~~follow:~~follows:


	Fiscal Quarter Ended												Fiscal Quarter Ended								Increase (Decrease)
	June 27, 2008				June 29, 2007				Increase (Decrease)				January 2, 2009				December 28, 2007				Increase (Decrease)
	$		% of Sales		$		% of Sales		$		%		$		% of Sales		$		% of Sales		$			%
(dollars in millions)
Geographic Region
North America	$	79.2	32.4	%	$	79.0	34.8	%	$	0.2	0.2	%	$	65.2	31.3	%	$	80.6	34.0	%	$	(15.4	)	(19.2	)%
Europe		98.1	40.1			90.4	39.8			7.7	8.5			83.9	40.3			96.2	40.5			(12.3	)	(12.8	)
Asia Pacific		51.5	21.1			47.4	20.9			4.1	8.8			47.1	22.6			47.8	20.1			(0.7	)	(1.4	)
Latin America		15.6	6.4			10.3	4.5			5.3	52.0			12.0	5.8			12.8	5.4			(0.8	)	(6.1	)

Total company	$	244.4	100.0	%	$	227.1	100.0	%	$	17.3	7.6	%	$	208.2	100.0	%	$	237.4	100.0	%	$	(29.2	)	(12.3	)%

The decrease in sales in North America ~~were essentially flat, with higher Vacuum Technologies sales offset by slightly~~was primarily attributable to lower Scientific Instruments sales (in particular, sales of research products) and, to a lesser extent, lower Vacuum Technologies sales. Reported sales outside North America were unfavorably impacted by the strengthening of the U.S. dollar compared to the first quarter of fiscal year 2008. The decrease in sales ~~increases~~ in Europe ~~and Asia Pacific were~~was also attributable to ~~higher~~lower sales byvolume of both ~~the~~ Scientific Instruments and Vacuum Technologies ~~segments. The~~products. Sales volume in Asia Pacific decreased slightly due to lower Vacuum Technologies sales, ~~increase~~while sales volume in Latin America ~~was attributable~~decreased slightly due to ~~higher~~lower Scientific Instruments sales.

The sales ~~increase~~decrease in ~~Europe~~North America was ~~less~~more pronounced compared to the prior-year quarter due to the timing of sales of certain low-volume, high-selling price ~~magnet-based~~research products. We do not consider this to be indicative of any particular trend for magnet-based products as a whole, but rather to be reflective of the variability in results that these low-volume, high-selling price magnet-based products can create.

Gross Profit. Gross profit for the ~~third~~first quarter of fiscal year 2009 reflects the impact of $1.6 million in amortization expense relating to acquisition-related intangible assets and $0.9 million in restructuring and other related costs. In comparison, gross profit for the first quarter of fiscal year 2008 reflects the impact of ~~$2.0~~$1.4 million in amortization expense relating to acquisition-related intangible assets, ~~$0.6~~amortization of $0.5 million ~~in amortization expense~~ related to inventory written up to fair value primarily in connection with the IonSpec acquisition ~~of Oxford Diffraction,~~and $0.5 million in restructuring and other related costs and share-based compensation expense of $0.1 million. In comparison, gross profit for the third quarter of fiscal year 2007 reflects the impact of $1.3 million in amortization expense relating to acquisition-related intangible assets, $0.7 million in restructuring and other related costs and share-based compensation expense of $0.1 million.costs. Excluding the impact of these items, the ~~decrease~~increase in gross profit as a percentage of sales was primarily the result of ~~higher transition costs related to~~ the ~~relocation of manufacturing activities for certain products, the weaker~~stronger U.S. dollar (which was favorable to reported ~~sales~~gross profit margins but unfavorable to reported ~~gross profit margins)~~sales) and ~~to a lesser extent, higher freight costs.~~the positive impact of efficiency improvements (such as those resulting from lower-cost manufacturing and outsourcing initiatives, global procurement initiatives, and facility relocations/closures) implemented in recent years.

Selling, General and Administrative. Selling, general and administrative expenses for the ~~third~~first quarter of fiscal year 2009 included $0.5 million in amortization expense relating to acquisition-related intangible assets and $0.6 million in restructuring and other related costs. In comparison, selling, general and administrative expenses for the first quarter of fiscal year 2008 included $0.4 million in amortization expense relating to acquisition-related intangible assets ~~$0.9~~and $1.2 million in restructuring and other related costs and $2.1 million in share-based compensation expense. In comparison, selling, general and administrative expenses for the third quarter of fiscal year 2007 included $0.5 million in amortization expense relating to acquisition-related intangible assets, $1.9 million in restructuring and other related costs and $1.9 million in share-based compensation expense.costs. Excluding the impact of these items, the ~~slight~~ increase in selling, general and administrative expenses as a percentage of sales was primarily due to the ~~weaker U.S. dollar, higher costs relating to new product introductions and the transition effect~~negative impact of ~~acquisitions completed during the quarter,~~lower sales volume, partially offset by ~~lower employee bonus accruals~~the favorable impact of the stronger U.S. dollar and the cost savings achieved from restructuring activities implemented in ~~the third quarter of fiscal year 2008.~~recent years.

Research and Development. Research and development expenses for the ~~third~~first quarter of fiscal year 2009 reflect the impact of restructuring and other related costs of $0.2 million. In comparison, research and development expenses for the first quarter of fiscal year 2008 reflect the impact of restructuring and other related costs of $0.3 ~~million and $0.1 million in share-based compensation expense. In comparison, research and development expenses for the third quarter of fiscal year~~

~~2007 reflect the impact of restructuring and other related costs of $0.3 million and share-based compensation expense of $0.1~~ million. Excluding the impact of these items, the ~~slight increase~~decrease in research and development expenses as a percentage of sales was primarily due to ~~higher~~the stronger U.S. dollar and lower costs ~~relating to~~associated with new product introductions ~~and product transition activities.~~

~~Purchased In-Process Research and Development.~~~~In connection with~~compared to the ~~Oxford Diffraction acquisition in the third~~first quarter of fiscal year 2008, we recorded a one-time charge of $1.5 million to immediately expense acquired in-process research and development related to projects that were in process but incomplete at the time of the acquisition.2008.

Restructuring Activities. ~~Between fiscal years 2003 and 2007, we~~We have committed to several restructuring plans in order to adjust our organizational structure, improve operational efficiencies, ~~and~~ eliminate redundant or excess costs resulting from acquisitions or dispositions during those ~~periods.From~~periods, and to otherwise reduce our costs.From the respective inception dates of these plans through ~~June 27, 2008,~~January 2, 2009, we have incurred a total of ~~$19.2~~$7.1 million in restructuring expense and a total of ~~$8.1~~$6.9 million in other costs related directly to those plans (comprised primarily of employee retention and relocation costs and accelerated depreciation of assets disposed upon the closure of facilities). During the ~~third~~first quarter of fiscal year ~~2008,~~2009, there was no significant activity under these plans except for the fiscal year 2007 plan and the fiscal year 2009 first quarter plan as described below.

Fiscal Year 2007 Plan. During the third quarter of fiscal year 2007, we committed to a plan to combine and optimize the development and assembly of most of our ~~NMR~~nuclear magnetic resonance (“NMR”) and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain

resources toward more rapidly growing product lines and geographies. As part of the plan, we are creating an information rich detection (“IRD”) center in Walnut Creek, California, where NMR operations ~~currently located in Palo Alto, California~~ are being integrated with mass spectrometry operations already located in Walnut Creek. Merging our IRD talent base into this single location will capitalize on our strength in NMR and mass spectrometry and enhance our ability to develop innovative IRD solutions that are more powerful, complementary, routine and user-friendly. Underscoring our commitment to IRD and the benefits that a combined location and organization will provide, we are investing in a new 45,000 square foot building and a substantial remodel of an existing building there to house the IRD center.

As a result of the plan, a number of employee positions have been or will be relocated or eliminated and certain facilities have been, or will be, consolidated. These actions primarily impact the Scientific Instruments segment and involve the elimination of between approximately 40 and 60 positions. We expect these activities to be completed during fiscal year 2009.

Restructuring and other related costs associated with this plan include one-time employee termination benefits, employee retention payments, costs to relocate facilities (including decommissioning costs, moving costs and temporary facility/storage costs), accelerated depreciation of fixed assets to be disposed as a result of facilities actions and lease termination costs.

The following table sets forth changes in our restructuring liability relating to the foregoing plan during the ~~third~~first quarter of fiscal year ~~2008~~2009 as well as total restructuring expense and other restructuring-related costs recorded since the inception of the plan:


		Employee- Related			Facilities- Related			Total				Employee- Related			Facilities- Related			Total
(in thousands)
Balance at March 28, 2008		$	1,585		$	756		$	2,341
Charges to expense, net			294			—			294
Balance at October 3, 2008												$	1,840		$	551		$	2,391
Reversals of expense, net													(387	)		—			(387	)
Cash payments			(107	)		(64	)		(171	)			—			(38	)		(38	)
Foreign currency impacts and other adjustments			(4	)		(11	)		(15	)			(2	)		17			15

Balance at June 27, 2008		$	1,768		$	681		$	2,449
Balance at January 2, 2009												$	1,451		$	530		$	1,981


Total expense since inception of plans
Total expense since inception of plan
(in millions)
Restructuring expense	Restructuring expense							$	3.9		Restructuring expense							$	4.0

Other restructuring-related costs	Other restructuring-related costs							$	4.7		Other restructuring-related costs							$	6.2

The reversals of restructuring ~~charges~~expense of ~~$0.3~~$0.4 million recorded during the ~~third~~first quarter of fiscal year ~~2008~~2009 related to changes in estimates relating to certain employee termination benefits. We also incurred ~~$1.4~~$0.8 million in other restructuring-related costs during the quarter, which were comprised of ~~$0.7~~$0.6 million in employee retention costs and ~~$0.7~~$0.2 million in facilities-related costs including decommissioning costs and a non-cash charge for accelerated depreciation of assets to be disposed upon the closure of facilities.

~~Income Tax Expense.~~Fiscal Year 2009 First Quarter Plan.~~The effective income tax rate was 37.5% for~~ During the ~~third~~first quarter of fiscal year 2008, compared to 33.4% for the third quarter of fiscal year 2007. The higher effective income tax rate in the third quarter of fiscal year 2008 was primarily due to higher U.S. taxes on foreign earnings, a non-deductible in-process research and development charge related to the acquisition of Oxford Diffraction in April 2008 and higher non-deductible compensation expense. These factors were partially offset by the benefit from a larger reduction in unrecognized tax benefits due to the lapse of certain statutes of limitations in the third quarter of fiscal year 2008.

~~Net Earnings~~. Net earnings for the third quarter of fiscal year 2008 reflect an acquisition-related in-process research and development charge of $1.5 million and the after-tax impacts of $2.4 million in acquisition-related intangible amortization, $0.6 million in amortization related to inventory written up to fair value in connection with the acquisition of Oxford Diffraction, $1.7 million in restructuring and other related costs and $2.3 million in share-based compensation expense. Net earnings for the third quarter of fiscal year 2007 reflect the after-tax impacts of $1.8 million in acquisition-related intangible amortization, $2.9 million in restructuring and other related costs and $2.1 million in share-based compensation expense. Excluding the after-tax impact of these items, the decrease in net earnings in the third quarter of fiscal year 2008 was primarily attributable to higher transition costs related to the relocation of manufacturing activities for certain products and higher costs relating to new product introductions.

~~We expect our initiatives to relocate manufacturing activities for certain products to have some residual negative impact on revenue and profitability in the fourth quarter of fiscal 2008.~~

~~First Nine Months of Fiscal Year 2008 Compared to First Nine Months of Fiscal Year 2007~~

The following table presents comparisons of our sales and operating earnings for each of our Scientific Instruments and Vacuum Technologies segments and in total for the first nine months of fiscal years 2008 and 2007:

~~Scientific Instruments~~. The increase in Scientific Instruments sales was primarily attributable to higher sales volume across a broad range of our analytical instruments and consumable products, partially offset by lower sales of magnet-based products. The weaker U.S. dollar and recent acquisitions also had a positive impact on Scientific Instruments sales growth. Sales increased for both industrial (which includes environmental, food and energy) and life science applications.

Scientific Instruments revenues for the first nine months of fiscal year 2007 do not include sales from acquisitions completed subsequent to that period, primarily Oxford Diffraction and the Analogix Business. Excluding sales from these acquisitions, Scientific Instruments sales in the first nine months of fiscal year 2008 increased by approximately 8% compared to the first nine months of fiscal year 2007.

Scientific Instruments operating earnings for the first nine months of fiscal year 2008 included an acquisition-related in-process research and development charge of $1.5 million, acquisition-related intangible amortization of $6.1 million, amortization of $1.2 million related to inventory written up to fair value in connection with the acquisitions of Oxford Diffraction, the Analogix Business and IonSpec Corporation (“IonSpec”), restructuring and other related costs of $4.2 million and share-based compensation expense of $2.6 million. In comparison, Scientific Instruments operating earnings for the first nine months of fiscal year 2007 included acquisition-related intangible amortization of $6.0 million, amortization of $0.5 million related to inventory written up to fair value in connection with the acquisition of IonSpec, restructuring and other related costs of $3.1 million and share-based compensation expense of $2.6 million. Excluding the impact of these items, operating earnings were lower as a percentage of sales due to higher transition costs related to the relocation of manufacturing activities for certain products, the continued weakening of the U.S. dollar (which was favorable to reported sales but unfavorable to reported operating margins) and the timing of new product introductions. These factors more than offset the positive impact of sales volume leverage.

~~Vacuum Technologies~~. The increase in Vacuum Technologies sales was driven by higher sales volume of a broad range of products and services, particularly those for industrial applications. The weaker U.S. dollar also had a positive impact on Vacuum Technologies sales growth.

Vacuum Technologies operating earnings for the first nine months of fiscal years 2008 and 2007 include the impact of share-based compensation expense of $0.6 million and $1.0 million, respectively. Excluding the impact of these items, the decrease in Vacuum Technologies operating earnings as a percentage of sales is primarily the result of the weaker U.S. dollar, which was only partially offset by the positive impact of sales volume leverage in the first nine months of fiscal year 2008.

~~The following table presents comparisons of our sales and other selected consolidated financial results for the first nine months of fiscal years 2008 and 2007:~~

~~Sales.~~ ~~As discussed under the heading~~~~Segment Results~~ above, sales by the Scientific Instruments and Vacuum Technologies segments in the first nine months of fiscal year 2008 increased by 8.7% and 5.9%, respectively, compared to the first nine months of fiscal year 2007. The growth in consolidated sales was broad-based, with increases in sales of products for both industrial and life science applications. Recent acquisitions and the weaker U.S. dollar also had a positive effect on the reported sales increases. Excluding sales from acquisitions completed since the third quarter of fiscal year 2007, consolidated sales in the first nine months of fiscal year 2008 increased by almost 8% compared to the first nine months of fiscal year 2007.

~~Sales by geographic region in the first nine months of fiscal years 2008 and 2007 were as follow:~~

The sales increases in North America and Latin America were driven by higher Scientific Instruments sales, with Vacuum Technologies sales essentially flat in those regions. The increases in sales in Europe and Asia Pacific were attributable to higher sales by both the Scientific Instruments and Vacuum Technologies segments.

The sales increase in Europe was less pronounced compared to the first nine months of fiscal year 2007 due to the timing of sales of certain low-volume, high-selling price magnet-based products. We do not consider this to be indicative of any particular trend for magnet-based products as a whole, but rather to be reflective of the variability in results that these low-volume, high-selling price magnet-based products can create.

~~Gross Profit~~. Gross profit for the first nine months of fiscal year 2008 reflects the impact of $4.9 million in amortization expense relating to acquisition-related intangible assets, $1.2 million in amortization expense related to inventory written up to fair value in connection with recent acquisitions, $1.2 million in restructuring and other related costs and share-based compensation expense of $0.3 million. In comparison, gross profit for the first nine months of fiscal year 2007 reflects the impact of $3.9 million in amortization expense relating to acquisition-related intangible assets, $0.5 million in amortization expense related to inventory written up to fair value in connection with the IonSpec acquisition, $0.7 million in restructuring and other related costs and share-based compensation expense of $0.3 million. Excluding the impact of these items, the decrease in gross profit as a percentage of sales was primarily the result of higher transition costs related to the relocation of manufacturing activities for certain products, the weaker U.S. dollar (which increased reported revenues but lowered reported gross profit margins) and, to a lesser extent, higher freight costs.

~~Selling, General and Administrative.~~ Selling, general and administrative expenses for the first nine months of fiscal year 2008 included $1.2 million in amortization expense relating to acquisition-related intangible assets, $2.3 million in restructuring and other related costs and $6.4 million in share-based compensation expense. In comparison, selling, general and administrative expenses for the first nine months of fiscal year 2007 included $2.1 million in amortization expense relating to acquisition-related intangible assets, $2.1 million in restructuring and other related costs and $7.1 million in share-based compensation expense. Excluding the impact of these items, the slight decrease in selling, general and administrative expenses as a percentage of sales was primarily the result of sales volume leverage and lower employee bonus accruals, largely offset by the continued weakening of the U.S. dollar, higher costs relating to sales commissions on strong orders, the timing of new product introductions and the transition effect of acquisitions completed during the first nine months of fiscal year 2008.

~~Research and Development~~. Research and development expenses for the first nine months of fiscal year 2008 reflect the impact of $0.8 million in restructuring and other related costs and share-based compensation expense of $0.3 million. In comparison, research and development expenses for the first nine months of fiscal year 2007 reflect the impact of $0.3 million in restructuring and other related costs and share-based compensation expense of $0.4 million. Excluding the impact of these items, research and development expenses were relatively flat as a percentage of sales.

~~Purchased In-Process Research and Development~~. In connection with the Oxford Diffraction acquisition in the third quarter of fiscal year 2008, we recorded a one-time charge of $1.5 million to immediately expense acquired in-process research and development related to projects that were in process but incomplete at the time of the acquisition.

~~Restructuring Activities~~. Between fiscal years 2003 and 2007, we committed to several restructuring plans in order to adjust our organizational structure, improve operational efficiencies and eliminate redundant or excess costs resulting from acquisitions or dispositions during those periods.During the first nine months of fiscal year 2008, there was no significant activity under these plans except for the fiscal year 2007 plan as described below.

~~Fiscal Year 2007 Plan~~~~. During the third quarter of fiscal year 2007,~~2009, we committed to a plan to ~~combine~~reduce our employee headcount in order to reduce operating costs and ~~optimize~~increase margins. The plan involves the termination of approximately 35 employees, mostly located in Europe. The restructuring costs related to this plan primarily consist of one-time termination benefits which are expected to be settled by the end of fiscal year 2011. This restructuring plan did not involve any non-cash components. Costs relating to restructuring activities recorded under this plan have been included in cost of sales, selling, general and administrative expenses and research and development and assembly of most of our NMR and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies.expenses.

The following table sets forth changes in our restructuring liability relating to the foregoing plan during the first ~~nine months~~quarter of fiscal year ~~2008:~~2009:


	Employee- Related			Facilities- Related			Total				Employee- Related			Facilities- Related		Total
(in thousands)
Balance at September 28, 2007	$	2,222		$	—		$	2,222
Balance at October 3, 2008											$	—		$	—	$	—
Charges to expense, net		798			761			1,559				1,312			—		1,312
Cash payments		(1,308	)		(185	)		(1,493	)			(601	)		—		(601	)
Foreign currency impacts and other adjustments		56			105			161				49			—		49

Balance at June 27, 2008	$	1,768		$	681		$	2,449
Balance at January 2, 2009											$	760		$	—	$	760


Total expense since inception of plan
(in millions)
Restructuring expense										Restructuring expense						$	1.3

~~The restructuring charges of $1.6 million recorded during~~Fiscal Year 2009 Second Quarter Plan (Subsequent Event). During the ~~first nine months~~second quarter of fiscal year ~~2008 related~~2009, we committed to ~~employee termination benefits~~a separate plan to reduce our cost structure, primarily through headcount reductions, due to continuing uncertainties in the global economic environment. The plan primarily involves the elimination of approximately 240 regular employees (primarily in North America and ~~costs associated with~~Europe and to a lesser extent Asia Pacific and Latin America) and 80 temporary positions in both the Scientific Instruments and Vacuum Technologies segments. In addition, the plan includes the closure of ~~leased facilities. We also~~one small R&D/manufacturing facility in North America (Lake Forest, California) and two sales offices in Europe (Sweden and Switzerland).

Restructuring and other related costs expected to be incurred ~~$2.7~~in connection with this plan are currently estimated to be between $8.5 million ~~in other restructuring-related costs~~and $10.5 million, of which ~~were comprised of $1.7~~between $8.0 million ~~in employee retention costs~~and $9.5 million is expected to impact the Scientific Instruments segment and between $0.5 million and $1.0 million ~~in facilities-related~~is expected to impact the Vacuum Technologies segment. The restructuring costs ~~including decommissioning~~are expected to include one-time termination benefits for employees whose positions are being eliminated of between $7.5 million and $9.0 million and lease termination costs of between $0.1 million and $0.2 million (including future lease payments on vacated facilities). Other restructuring-related costs are expected to include employee retention and relocation costs of between $0.3 million and $1.0 million and facility-related relocation costs and ~~a non-cash charge for~~ accelerated depreciation of fixed assets to be disposed upon the closure of ~~facilities.~~facilities of between $0.1 million and $0.3 million. These costs will be recorded and included in cost of sales, selling, general and administrative expenses and research and development expenses.

Most of these costs are expected to be recorded and settled during fiscal year 2009, although certain one-time termination benefits are expected to be settled in fiscal year 2010. Non-cash costs are not expected to be material under the plan.

~~Impairment~~Restructuring Cost Savings. The following table sets forth the estimated annual cost savings for each plan, when they were initiated, as well as where those cost savings were expected to be realized:

These estimated cost savings are expected to impact cost of ~~Private Company Equity Investment.~~sales, selling, general and administrative expenses and research and development expenses. Some of these cost savings have been and will continue to be reinvested in other parts of our business, for example, as part of our continued emphasis on IRD and consumable products. In addition, unrelated cost increases in other areas of our operations have and could in the future offset some or all of these cost savings. Although it is difficult to quantify with any precision our actual cost savings to date from these activities, many of which are still ongoing, we currently believe that the ultimate savings realized will not differ materially from these estimates.

Interest Income. ~~During~~The decrease in interest income was primarily due to lower average invested cash balances and lower rates of interest on those balances during the first ~~nine months~~quarter of fiscal year ~~2008, we became aware of information which raised substantial doubt about~~2009 compared to the ability of a small, private company in which we hold a cost-method equity investment to continue as a going concern. Based on this information, we determined that the fair value of our investment had declined and that the decline was other-than-temporary. As a result, we wrote off the entire $3.0 million carrying value via an impairment charge in the secondfirst quarter of fiscal year 2008.

Income Tax Expense.The effective income tax rate was ~~35.4%~~35.3% for the first ~~nine months~~quarter of fiscal year ~~2008,~~2009, compared to ~~34.5%~~31.4% for the first ~~nine months~~quarter of fiscal year ~~2007.~~2008. The ~~higher~~lower effective income tax rate in the first ~~nine months~~quarter of fiscal year 2008 was primarily due to ~~higher U.S. taxes on foreign earnings, higher non-deductible compensation expense and a non-deductible in-process research and development charge related to~~ the ~~acquisition~~release of ~~Oxford Diffraction~~$1.5 million in ~~April 2008. These factors were partially offset by~~tax reserves resulting from the ~~benefit from a larger reduction in unrecognized~~positive outcome of tax ~~benefits due to the lapse of certain statutes of limitations in the first nine months of fiscal year 2008.~~uncertainties during that period.

Net Earnings. Net earnings for the first ~~nine months~~quarter of fiscal year 2009 reflect the after-tax impacts of $2.1 million in pre-tax acquisition-related intangible amortization and $1.7 million in pre-tax restructuring and other related costs. Net earnings for the first quarter of fiscal year 2008 reflect ~~an in-process research and development charge of $1.5 million and~~ the after-tax impacts of ~~an impairment of a private company equity~~

investment of $3.0 million, $6.1 million in acquisition-related intangible amortization, $1.2 million in amortization related to inventory written up to fair value in connection with recent acquisitions, $4.2 million in restructuring and other related costs and $7.0 million in share-based compensation expense. Net earnings for the first nine months of fiscal year 2007 reflect the after-tax impacts of $6.0$1.8 million in acquisition-related intangible amortization, $0.5 million in amortization related to inventory written up to fair value in connection with the acquisition of IonSpec ~~$3.1~~and $2.0 million in restructuring and other related ~~costs and $7.8 million in share-based compensation expense.~~costs. Excluding the after-tax impact of these items, the ~~increase~~decrease in net earnings in the first ~~nine months~~quarter of fiscal year ~~2008~~2009 was primarily attributable to ~~higher~~the negative impact of lower sales ~~volume (including sales volume leverage on operating expenses), partially offset by higher transition costs related~~volume.

We believe that we are well-positioned from an earnings and cash flow standpoint, with a broad portfolio of products and applications, a global distribution network, recurring revenues from after-sales consumable products and services, a reduced cost structure and, if they hold, improved currency exchange rates relative to the ~~relocation~~U.S. dollar. However, we are operating in difficult global economic conditions and are facing unprecedented economic uncertainties that make it difficult for us to project our near-term results of ~~manufacturing activities for certain products~~operations. We experienced a year-over-year decline in customer orders at the end of our first quarter of fiscal year 2009, which weakness continued to a lesser extent through the first month of the second quarter of fiscal year 2009. Given this order weakness and ~~higher costs relating to new product introductions.~~global economic conditions, our results in the first quarter of fiscal year 2009 might not be indicative of our future results. These conditions could worsen and have an adverse effect on our financial position, results of operations and/or cash flows.

We generated ~~$59.6~~$16.9 million of cash from operating activities in the first ~~nine months~~quarter of fiscal year ~~2008,~~2009, compared to ~~$59.3~~$17.1 million generated in the first nine months of fiscal year 2007. Cash generated from operating activities remained essentially flat as a relative increase in inventories ($21.3 million) was offset by a relative decrease in accounts receivable ($8.5 million) and relative increases in accrued liabilities ($2.9 million) and accounts payable ($7.7 million). The relative increase in inventories was primarily due to a build-up of inventory to support increased orders, new product introductions and the transition of certain products to new manufacturing locations. The relative decrease in accounts receivable was primarily due to stronger collection efforts in the first nine monthsquarter of fiscal year 2008. ~~The relative increase~~Despite lower net earnings and higher payments related to payroll-related accruals in ~~accrued liabilities was primarily due to an increase in contract advances from customers during~~ the first ~~nine months~~quarter of fiscal year ~~2008. The relative increase in accounts payable was~~2009, operating cash flows were comparable to the prior-year quarter due primarily ~~due~~ to the favorable impact of increased cash collections (from higher ~~purchasing of inventories.~~prior-quarter revenues) and reduced inventory purchases (to align with current-quarter revenue levels).

We used ~~$68.3~~$2.5 million of cash for investing activities in the first ~~nine months~~quarter of fiscal year ~~2008,~~2009, which compares to ~~$12.8~~$13.1 million used for investing activities in the first ~~nine months~~quarter of fiscal year ~~2007. The increase~~2008. In October 2008, we entered into an agreement with VMS under which we agreed to surrender to them the sublease for our facility in ~~cash~~Palo Alto, California in exchange for $21.0 million. We received a $5.0 million non-refundable first surrender payment under this agreement in the first quarter of fiscal year 2009 and will receive the remaining $16.0 million

when we fully surrender the facility in the third quarter of fiscal year 2010. During the first quarter of fiscal year 2009, we also made investments totaling $6.9 million related to property, plant and equipment, which primarily related to the construction of our new IRD facility in Walnut Creek, California. Cash used for investing activities in the first ~~nine months~~quarter of fiscal year 2008 ~~was~~consisted primarily of consideration for the ~~result of the acquisitions~~acquisition of the Analogix Business in November ~~2007 and Oxford Diffraction in April 2008 as well as higher net capital expenditures due primarily to the construction of our IRD center in Walnut Creek, California.~~2007.

We ~~used $69.8~~generated $0.5 million of cash ~~for~~from financing activities in the first ~~nine months~~quarter of fiscal year ~~2008,~~2009, which compares to ~~$38.6~~$3.4 million used for financing activities in the first ~~nine months~~quarter of fiscal year ~~2007. The increase in cash~~2008. Cash used for financing activities in the first ~~nine months~~quarter of fiscal year 2008 was higher primarily ~~due to~~as a result of higher expenditures to repurchase and retire common stock (such expenditures were made in ~~both periods~~the period as a result of ~~a continued~~an effort to utilize excess cash to reduce the number of outstanding common shares), ~~lower~~partially offset by higher proceeds from the issuance of common stock (due to ~~lower~~higher stock option exercise volume) ~~and higher repayments of debt.~~.

We maintain relationships with banks in many countries from whom we sometimes obtain bank guarantees and short-term standby letters of credit. These guarantees and letters of credit relate primarily to advance payments and deposits made to our subsidiaries by customers for which separate liabilities are recorded in the unaudited condensed consolidated financial statements. As of ~~June 27, 2008,~~January 2, 2009, a total of ~~$23.2~~$20.5 million of these bank guarantees and letters of credit were outstanding. No amounts had been drawn by beneficiaries under these or any other outstanding guarantees or letters of credit as of that date.

As of ~~June 27,~~both January 2, 2009 and October 3, 2008, we had an $18.8 million term loan outstanding with a U.S. financial ~~institution. The balance outstanding under this term loan was $25.0 million~~institution at ~~September 28, 2007. As of both June 27, 2008 and September 28, 2007, the~~a fixed interest rate ~~on the term loan was~~of 6.7%. The term loan contains certain covenants that limit future borrowings and the payment of cash dividends and require the maintenance of certain levels of working capital and operating results. We were in compliance with all restrictive covenants of the term loan agreement at ~~June 27, 2008.~~

In connection with certain acquisitions, we have accrued a portion of the purchase price that has been retained to secure the ~~respective~~ sellers’ indemnification obligations. ~~The following table summarizes outstanding purchase price amounts~~As of January 2, 2009 we had retained ~~and the date they~~an aggregate of $1.6 million, which will become payable (net of any indemnification claims) ~~as of June 27, 2008:~~

~~In addition to the above amounts, the final $0.7 million retained in connection with the acquisition of IonSpec in February 2006 was paid during the first nine months of fiscal year 2008.~~between April and November 2009.

As of ~~June 27, 2008,~~January 2, 2009, we had several outstanding contingent consideration arrangements relating to acquired businesses. Amounts subject to these arrangements can be earned over the respective measurement period, depending on the performance of the acquired business relative to certain financial and/or operational targets.

The following table summarizes contingent consideration arrangements as of ~~June 27, 2008:~~January 2, 2009:

During the first ~~nine months~~quarter of fiscal year ~~2008,~~2009, we paid ~~$4.0~~$0.5 million ~~for the final~~in contingent consideration ~~payment related~~ to ~~Magnex Scientific Limited, which we acquired in November 2004.~~the seller of the Analogix Business.

The Distribution Agreement provides that we are responsible for certain litigation to which VAI was a party, and further provides that we will indemnify VMS and VSEA for one-third of the costs, expenses and other

liabilities relating to certain discontinued, former and corporate operations of VAI, including certain environmental liabilities (see Note 1213 of the Notes to the Unaudited Condensed Consolidated Financial Statements).

As of ~~June 27, 2008,~~January 2, 2009, we had cancelable commitments to a contractor for capital expenditures totaling approximately ~~$21.3~~$12.1 million relating to the construction of our IRD center in Walnut Creek, California. In the event that these commitments are canceled for reasons other than the contractor’s default, we may be responsible for reimbursement of actual costs incurred by the contractor. We had no material non-cancelable commitments for capital expenditures as of ~~June 27, 2008.~~January 2, 2009. In the aggregate, we currently anticipate that our capital expenditures will be approximately 2.5% to 3.0% of sales for ~~the full~~ fiscal year ~~2008.~~2009.

As discussed above under the headingRestructuring Activities, in April 2007, we committed to a plan to combine and optimize the development and assembly of most of our NMR and mass spectrometry products, to further centralize related administration and other functions and to reallocate certain resources toward more rapidly growing product lines and geographies. In connection with this plan, we expect to make capital expenditures of up to ~~$25~~$30.7 million, of which $15.1 million has been spent through January 2, 2009. These capital expenditures began in the fourth quarter of fiscal year 2007 and will continue through

In connection with all of ~~these expenditures will fall within~~ our ~~typical capital spending pattern (of approximately 3% of sales) measured over a two-year period. We also~~restructuring plans, including the fiscal year 2009 second quarter plan, we expect to ~~incur total~~make cash payments for restructuring and other related costs ~~associated with this plan of~~totaling between ~~$12.0~~approximately $10 million and ~~$14.0~~$14 million during fiscal year 2009, of which ~~$4.3~~$1.0 million was ~~incurred in fiscal year 2007 and $4.2 million was incurred in~~paid during the first ~~nine months of fiscal year 2008. Some portion of these costs is expected to be settled through the fourth~~ quarter of fiscal year 2009, except for certain lease termination-related costs, which might be settled as late as the fourth quarter of fiscal year 2012. A total of $10.5 million to $12.5 million of these costs are expected to result in cash expenditures.2009.

In February 2008, our Board of Directors approved a ~~new~~ stock repurchase program under which we are authorized to utilize up to $100 million to repurchase shares of our common stock. This repurchase program is effective through December 31, 2009. During the ~~nine months ended June 27, 2008,~~first quarter of fiscal year 2009, we ~~repurchased and retired 567,000~~did not purchase any shares under this ~~authorization at an aggregate cost of $30.5 million.~~authorization. As of ~~June 27, 2008,~~January 2, 2009, we had remaining authorization to repurchase ~~$69.5~~$44.6 million of our common stock under ~~this repurchase program.~~

In January 2007, our Board of Directors approved a stock repurchase program under which we were authorized to utilize up to $100 million to repurchase shares of our common stock. This repurchase program was effective until December 31, 2008. During the first nine months of fiscal year 2008, we repurchased and retired 876,000 shares under this repurchase program at an aggregate cost of $50.4 million, which completed this repurchase program.

Our liquidity is affected by many other factors, some based on the normal ongoing operations of ~~the~~our business and others related to external economic conditions. Our liquidity has not been materially affected by the ~~uncertainties~~recent deterioration in the global financial markets or global economic conditions in general. However, this deterioration has adversely impacted the availability of ~~the industries~~credit to us as well as to our customers and suppliers.

We have no material exposure to market risk for changes in ~~which~~interest rates or investment valuations. Our outstanding debt carries a fixed interest rate, and we ~~compete~~invest our excess cash primarily in depository accounts and money market funds at various financial institutions. While we have not historically needed to borrow to support working capital or capital expenditure requirements, there is no assurance that we might not need to borrow to support these requirements given global ~~economies. Although~~economic conditions. This could also adversely affect our ~~cash requirements will fluctuate based on the timing~~ability to complete acquisitions and ~~extent of these factors, we~~repurchase our common stock.

We nonetheless believe that cash generated from operations, together with our current cash ~~balance~~ and cash equivalents balances and current borrowing capability, will be sufficient to satisfy ~~commitments for capital expenditures and other~~our cash requirements for the next 12 months. There can be no assurance, however, that our business will continue to generate cash flows at current levels or that credit will be available to us if and when needed. Future operating performance and our ability to obtain credit will be subject to future economic conditions and to financial, business and other factors.

The following table summarizes the amount and estimated timing of future cash expenditures relating to principal and interest payments on outstanding long-term debt, minimum rentals due for certain facilities and other leased assets under long-term, non-cancelable operating leases and other long-term liabilities as of ~~June 27, 2008:~~January 2, 2009:


	Fiscal Quarter Ending Oct. 3, 2008		Fiscal Years														Nine Months Ending Oct. 2, 2009			Fiscal Years																	Total
	Fiscal Quarter Ending Oct. 3, 2008		2009		2010		2011		2012		2013		Thereafter		Total				2010			2011			2012			2013			2014			Thereafter			Total
(in thousands)																	Nine Months Ending Oct. 2, 2009
Operating leases	$	3,001	$	9,472	$	6,683	$	3,356	$	2,252	$	1,780	$	3,762	$	30,306	$	6,967		$	7,204		$	3,987		$	2,373		$	3,262		$	—		$	1,899	$	25,692
Long-term debt (including current portion)		—		—		6,250		—		6,250		—		6,250		18,750
Long-term debt																		—			6,250			—			6,250			—			6,250			—		18,750
Interest on long-term debt																		942			1,152			838			733			419			314			—		4,398
Other long-term liabilities		502		4,455		3,898		3,511		2,934		2,742		26,164		44,206		2,461			8,611			3,626			3,010			2,728			2,619			23,857		46,912

Total	$	3,503	$	13,927	$	16,831	$	6,867	$	11,436	$	4,522	$	36,176	$	93,262	$	7,909		$	25,678		$	8,451		$	12,366		$	6,409		$	9,183		$	25,756	$	95,752

As of ~~June 27, 2008,~~January 2, 2009, we did not have any off-balance sheet commercial commitments that could result in a significant cash outflow upon the occurrence of some contingent event, except for contingent payments of up to a maximum of ~~$43.9~~$28.1 million related to acquisitions as discussed underLiquidity and Capital Resources above, the specific amounts of which are not currently determinable.

In September 2006, the FASB issued SFAS 157, Fair Value Measurements,~~. SFAS 157~~ which defines fair value, establishes a framework for measuring fair value ~~in generally accepted accounting principles~~ and expands disclosures about fair value measurements. SFAS 157 applies to previous accounting pronouncements that require or permit fair value measurements. SFAS 157 is effective for fiscal years beginning after November 15, 2007, with certain exceptions which are described below. In ~~February 2008, the FASB issued FASB Staff Position (“FSP”) 157-1,~~ Application of FASB Statement No. 157 to FASB Statement No. 13 and Other Accounting Pronouncements That Address Fair Value Measurements for Purposes of Lease Classification or Measurement under Statement 13~~, which amends SFAS 157 to exclude certain leasing transactions from its scope. Also in~~ February 2008, the FASB issued FSP 157-2,Effective Date of FASB Statement No. 157,which delays the effective date of SFAS 157 for all nonfinancial assets and nonfinancial liabilities to fiscal years beginning after November 15, 2008, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). We adopted SFAS 157 effective October 4, 2008 with the exception of the application of the statement to nonrecurring nonfinancial assets and nonfinancial liabilities (see Note 4). We do not expect the adoption of ~~SFAS 157~~the provisions deferred by FSP 157-2 to have a material impact on our financial condition or results of operations.

In ~~February 2007, the FASB issued SFAS 159,~~~~The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement 115~~, which provides companies with an option to measure eligible financial assets and liabilities in their entirety at fair value. The fair value option may be applied instrument by instrument, and may be applied only to entire instruments. If a company elects the fair value option for an eligible item, changes in the item’s fair value must be reported as unrealized gains and losses in earnings at each subsequent reporting date. SFAS 159 is effective for fiscal years beginning after November 15, 2007. We are evaluating the options provided under SFAS 159 and their potential impact on our financial condition and results of operations if implemented.

In December 2007, the FASB issued SFAS ~~141(revised~~141 (revised 2007),Business Combinations, (“SFAS 141(R)”). SFAS 141(R) retains the fundamental requirements of the original pronouncement requiring that the purchase method be used for all business combinations but also provides revised guidance for recognizing and measuring identifiable assets and goodwill acquired, liabilities assumed, and any noncontrolling interest in the acquiree. It also requires the recognition of assets acquired and liabilities assumed arising from contingencies, the capitalization of in-process research and development at fair value, and the expensing of acquisition-related costs as incurred.SFAS 141(R) is effective for fiscal years beginning after December 15, 2008. We ~~are currently evaluating the requirements of SFAS 141(R) and~~ do not expect its adoption in the first quarter of fiscal year 2010 to have a material impact on our financial condition or results of operations. However, in the event that we complete acquisitions subsequent to our adoption of SFAS 141(R), the application of its provisions will likely have a material impact on our results of operations, although we are not currently able to estimate that impact.

disclosures are required to clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS 160 is effective for fiscal years beginning after December 15, 2008, and requires retroactive adoption of the presentation and disclosure requirements for existing minority interests. All other requirements are applied prospectively. We do not expect the adoption of SFAS 160 to have a material impact on our financial condition or results of operations.

related hedged items on our financial condition and results of operations. SFAS 161 is effective for fiscal years beginning after November 15, 2008. We do not expect the adoption of SFAS 161 to have a material impact on our financial condition or results of operations.

In April 2008, the FASB issued FSP 142-3,Determination of the Useful Life of Intangible Assets, which amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset. The intent of FSP 142-3 is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142,Goodwill and Other Intangible Assets, and the period of expected cash flows used to measure the fair value of the asset under SFAS 141(R),Business Combinations, and other accounting literature. FSP 142-3 is effective for fiscal years beginning after December 15, 2008 and must be applied prospectively to intangible assets acquired after the effective date. Early adoption is prohibited. Given that FSP 142-3 applies to intangible assets acquired after the effective date, we ~~are~~do not ~~yet able to determine whether~~expect its adoption ~~will~~to have a material impact on our financial condition or results of operations.

In December 2008, the FASB issued FSP 132(R)-1,Employers’ Disclosures about Postretirement Benefit Plan Assets. FSP 132(R)-1 amends SFAS 132 (revised 2003),Employers’ Disclosures about Pensions and Other Postretirement Benefits, to provide guidance on an employer’s disclosures about plan assets of a defined benefit pension or other postretirement plan. This FSP is effective for fiscal years ending after December 15, 2009. We do not expect the adoption of FSP 132(R)-1 to have a material impact on our financial condition or results of operations.

Foreign Currency Exchange Risk. We enter into foreign exchange forward contracts to minimize the short-term impact of foreign currency fluctuations on assets and liabilities denominated in non-functional currencies. From time to time, we also enter into foreign exchange forward contracts to minimize the impact of foreign currency fluctuations on forecasted transactions. The success of our hedging activities depends on our ability to forecast balance sheet exposures and transaction activity in various foreign currencies. To the extent that these forecasts are overstated or understated during periods of currency volatility, we could experience unanticipated currency gains or losses. However, we believe that in most cases any such gains or losses would be substantially offset by losses or gains from the related foreign exchange forward contracts. We therefore believe that the direct effect of an immediate 10% change in the exchange rate between the U.S. dollar and all other currencies is not reasonably likely to have a material adverse effect on our financial condition or results of operations.

At ~~June 27, 2008,~~January 2, 2009, there were no outstanding forward contracts designated as cash flow hedges of forecasted transactions. During the first ~~nine months~~quarter of fiscal year ~~2008,~~2009, no foreign exchange gains or losses from cash flow hedge ineffectiveness were recognized.

Our foreign exchange forward contracts generally range from one to 12 months in original maturity. A summary of all foreign exchange forward contracts that were outstanding as of ~~June 27, 2008~~January 2, 2009 follows:


	Notional Value Sold		Notional Value Purchased		Notional Value Sold		Notional Value Purchased
(in thousands)
Australian dollar	$	—	$	43,281	$	—	$	45,869
Euro		—		28,715		—		32,594
British pound		—		11,971		—		15,238
Swiss franc		—		4,510
Japanese yen						3,751		—
Korean won						3,079		—
Brazilian real						1,654		—
Canadian dollar		3,255		—		1,313		—
Japanese yen		3,248		—
Mexican peso						—		1,119
Swedish krona		2,337		—		1,050		—
Polish zloty		—		1,634		—		473

Total	$	8,840	$	90,111	$	10,847	$	95,293

Interest Rate Risk. We have no material exposure to market risk for changes in interest rates. We invest any excess cash primarily in ~~short-term U.S. Treasury securities~~depository accounts and money market funds, and changes in interest rates would not be material to our financial condition or results of operations. We enter into debt obligations principally to support general corporate purposes, including working capital requirements, capital expenditures and acquisitions. At ~~June 27, 2008,~~January 2, 2009, our debt obligations had fixed interest rates.

Based upon rates currently available to us for debt with similar terms and remaining maturities, the carrying amounts of long-term debt approximate their estimated fair values.

Although payments under certain of our operating leases for our facilities are tied to market indices, we are not exposed to material interest rate risk associated with our operating leases.

Principal Amounts and Related Weighted-Average Interest Rates By Year of Maturity


	Fiscal Quarter Ending Oct. 3, 2008			Fiscal Years																		Total			Nine Months Ending Oct. 2,			Fiscal Years
	Fiscal Quarter Ending Oct. 3, 2008			2009			2010			2011			2012			2013			Thereafter			Total			2009			2010			2011			2012			2013			2014			Thereafter			Total
(in thousands)
Long-term debt (including current portion)	$	—		$	—		$	6,250		$	—		$	6,250		$	—		$	6,250		$	18,750
Long-term debt																									$	—		$	6,250		$	—		$	6,250		$	—		$	6,250		$	—		$	18,750
Average interest rate		—	%		—	%		6.7	%		—	%		6.7	%		—	%		6.7	%		6.7	%		—	%		6.7	%		—	%		6.7	%		—	%		6.7	%		—	%		6.7	%

Defined Benefit Retirement Plans. Most of our retirement plans, including all U.S.-based plans, are defined contribution plans. However, we also provide defined benefit pension plans in certain countries outside of the U.S. Our obligations under these defined benefit plans will ultimately be settled in the future and are therefore subject to estimation. Defined benefit pension accounting under SFAS 87,Employers’ Accounting for Pensions, is intended to reflect the recognition of future benefit costs over the employees’ estimated service periods based on the terms of the pension plans and the investment and funding decisions made by us.

For our defined benefit pension plans, we make assumptions regarding several variables including the expected long-term rate of return on plan assets and the discount rate in order to determine defined benefit pension plan expense for the year. This expense is referred to as “net periodic pension cost.” We assess the expected long-term rate of return on plan assets and discount rate assumption for each defined benefit plan based on relevant market conditions as prescribed by SFAS 87 and make adjustments to the assumptions as appropriate. On an annual basis, we analyze the rates of return on plan assets and discount rates used and determine that these rates are reasonable. For rates of return, this analysis is based on a review of the nature of the underlying assets, the allocation of those assets and their historical performance and expectations relative to ~~the overall~~relevant markets in the countries where the related plans are effective. Historically, our assumed asset allocations have not varied significantly from the actual allocations. Discount rates are based on the prevailing market long-term interest rates in the countries where the related plans are effective. As of ~~September 28, 2007,~~October 3, 2008, the estimated long-term rate of return on our defined benefit pension plan assets ranged from ~~0.5%~~0.8% to 7.1% (weighted-average of ~~5.9%~~5.8%), and the assumed discount rate for our defined benefit pension plan obligations ranged from 2.0% to ~~5.7%~~6.1% (weighted-average of ~~5.5%~~6.0%).

If any of these assumptions were to change, our net periodic pension cost would also change. We incurred net periodic pension cost relating to our defined benefit pension plans of $1.5 million in fiscal year 2008, $2.3 million in fiscal year 2007 and $2.3 million in fiscal year 2006, ~~and $1.6 million in fiscal year 2005 (excluding a settlement loss),~~ and expect our net periodic pension cost to be approximately ~~$1.7~~$1.6 million in fiscal year ~~2008.~~2009. A one percent decrease in the weighted-average estimated return on plan assets or assumed discount rate would increase our net periodic pension cost for fiscal year ~~2008~~2009 by ~~$1.1~~$1.0 million or $0.4 million, respectively. As of ~~September 28, 2007,~~October 3, 2008, our projected benefit obligation relating to defined benefit pension plans was ~~$53.3~~$47.7 million. A one percent decrease in the weighted-average estimated discount rate would increase this obligation by ~~$11.0~~$9.8 million.

Disclosure Controls and Procedures. Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our Chief Executive Officer and the Chief Financial Officer have concluded that as of the end of the period covered by this Quarterly Report on Form 10-Q ~~(June 27, 2008)~~(for the period ended January 2, 2009), our disclosure controls and procedures were effective.

Inherent Limitations on the Effectiveness of Controls. The Company’s management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons or by collusion of two or more people. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Control over Financial Reporting. There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the ~~third~~first quarter of our fiscal year ~~2008~~2009 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

See Item 1A—Risk Factors presented in our Annual Report on Form 10-K for the fiscal year ended ~~September 28, 2007,~~October 3, 2008, which we encourage you to carefully consider.

(c) During the fiscal quarter ended January 2, 2009 ~~February 2008 Stock Repurchase Program.~~,~~The following table summarizes information relating~~ the Company repurchased and retired 8,000 shares tendered to ~~our stock repurchases during~~it by employees in settlement of employee tax withholding obligations due from those employees upon the ~~third quarter~~vesting of ~~fiscal year 2008:~~restricted stock.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Delaware		77-0501995
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

3120 Hansen Way, Palo Alto, California		94304-1030
(Address of Principal Executive Offices)		(Zip Code)


Large accelerated filer x		Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)		Smaller reporting company ¨


		Page

PART I	Financial Information

Item 1.	Financial Statements:

	Unaudited Condensed Consolidated Statement of Earnings	3

	Unaudited Condensed Consolidated Balance Sheet	4

	Unaudited Condensed Consolidated Statement of Cash Flows	5

	Notes to the Unaudited Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2422

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3832

Item 4.	Controls and Procedures	4034

PART II	Other Information

Item 1A.	Risk Factors	4135

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4135

Item 6.	Exhibits	4135


Acquired Company/Business	Remaining Amount Available (maximum) ~~(maximum)~~			Measurement Period		Measurement Period End Date
	(in ~~millions)~~millions	)
~~PL International Ltd.~~	~~$15.3~~		~~3 years~~		~~December 2008~~
IonSpec Corporation	14.0			3 years		April 2009
Oxford Diffraction Limited	10.0			3 years		April 2011
Analogix Business	~~4.0~~3.5			3 years		December 2010
Other	0.6			2 years		July 2010

Total	$~~43.9~~28.1


	Scientific Instruments		Vacuum Technologies		Total Company
(in thousands)
Balance as of September 28, 2007	$	192,794	$	966	$	193,760
Fiscal year 2008 acquisitions		29,247		—		29,247
Contingent payments on prior-year acquisitions		4,057		—		4,057
Foreign currency impacts and other adjustments		3,366		—		3,366

Balance as of June 27, 2008	$	229,464	$	966	$	230,430


	Fair Value Measurements Using Input Type
	Level 1		Level 2		Level 3		Total
(in thousands)
Assets:
Money market funds (cash equivalents)	$	25,095	$	—	$	—	$	25,095

Total financial assets	$	25,095	$	—	$	—	$	25,095


	September 28, 2007
	Gross		Accumulated Amortization			Net
(in thousands)
Intangible assets
Existing technology	$	16,611	$	(8,235	)	$	8,376
Patents and core technology		29,908		(10,752	)		19,156
Trade names and trademarks		2,458		(1,623	)		835
Customer lists		11,866		(9,408	)		2,458
Other		3,025		(2,278	)		747

Total	$	63,868	$	(32,296	)	$	31,572


	Sales				Pretax Earnings
	Fiscal Quarter Ended				Fiscal Quarter Ended
	January 2, 2009		December 28, 2007		January 2, 2009			December 28, 2007
(in millions)
Scientific Instruments	$	171.8	$	197.0	$	16.4		$	19.8
Vacuum Technologies		36.4		40.4		7.0			7.7

Total industry segments		208.2		237.4		23.4			27.5
General corporate		—		—		(3.6	)		(3.4	)
Interest income		—		—		0.6			1.9
Interest expense		—		—		(0.3	)		(0.4	)

Total	$	208.2	$	237.4	$	20.1		$	25.6


Restructuring Plan		Estimated Annual Cost Savings
Fiscal Year 2007 Plan (Scientific Instruments - to combine and optimize the development and assembly on certain products and to centralize functions and reallocate resources to rapidly growing product lines)		$3 million - $5 million
Fiscal Year 2009 First Quarter Plan (Scientific Instruments - to reduce headcount and operating costs and increase operating margins)		$2 million - $3 million
Fiscal Year 2009 Second Quarter Plan (Scientific Instruments and Vacuum Technologies - to reduce its cost structure, primarily through headcount reduction)		$20 million - $24 million


~~Acquired Business~~	~~Retained Amount~~	~~Date Payable~~
	~~(in millions)~~
~~Analogix Business~~	~~$1.3~~	~~November 2009~~
~~Other~~	~~0.3~~	~~April 2009~~

~~Total~~	~~$1.6~~


Acquired Company/ Business	Remaining Amount Available (maximum)	Measurement Period	Measurement Period End Date
	(in millions)
~~PL International Ltd.~~	~~$15.3~~	~~3 years~~	~~December 2008~~
IonSpec Corporation	14.0	3 years	April 2009
Oxford Diffraction Limited	10.0	3 years	April 2011
Analogix Business	~~4.0~~3.5	3 years	December 2010
Other	0.6	2 years	July 2010

Total	$~~43.9~~28.1


Fiscal Month	Shares Repurchased ⁽¹⁾	Average Price Per Share⁽¹⁾		Total Value of Shares Repurchased as Part of Publicly Announced Plan⁽²⁾⁽³⁾		Maximum Total Value of Shares that May Yet Be Purchased Under the Plan
(in thousands, except per share amount)
Balance – March 28, 2008						$	79,752
March 29, 2008 – April 25, 2008	—	$	—	$	—	$	79,752
April 26, 2008 – May 23, 2008	152		53.25		7,987	$	71,765
May 24, 2008 – June 27, 2008	42		54.46		2,260	$	69,505

Total shares repurchased	194	$	53.51	$	10,247


		Incorporated by Reference			Filed Herewith
Exhibit No.	Exhibit Description	~~Incorporated by~~ ~~Reference~~			Filed Herewith
	Form	Date	Exhibit Number	~~Filed~~ ~~Herewith~~

~~31.1~~ 10.31*	~~Certification~~ Description of ~~Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.~~Compensatory Arrangements between Varian, Inc. and Non-Employee Director				X

~~31.2~~ 31.1	Certification of Chief ~~Financial~~Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X

31.2	~~32.1~~Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X

32.1	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

VARIAN, INC.
(Registrant)

Date: ~~August 5, 2008~~February 11, 2009

/s/S/ G. EDWARD MCCLAMMY

G. Edward McClammy
Senior Vice President and Chief Financial Officer
~~and Treasurer~~
(Duly Authorized Officer and
Principal Financial Officer)